



Inside THIS ISSUE

Feature Articles

- Do Outcomes of Prostatectomy Vary Among Surgeons?9
- Impact of Decreasing Shock Wave Delivery Rate10
- How to Use Medications for OAB11
- Surgical Treatment Options for Peyronie's Disease15

Feature Columns

- What are Red Flags Rules?20
- How to Increase the Talent Pool in Urological Research21
- New Basic Science Symposium Coming in 201122
- Cello Scrotum24

Have You Read?18

Managing Your Practice23

Calendar of Events26

HEY Bob!

Comparison of NCCN and AUA Prostate Cancer Treatment Guidelines

NCCN Guidelines

Dr. Stéfanie A. Seixas-Mikelus
Dr. James L. Mohler
 National Comprehensive Cancer Network
 Guidelines Panel for Prostate Cancer Chair
 Buffalo, New York

The National Comprehensive Cancer Network (NCCN) issued updates to the Clinical Practice Guidelines on Oncology-Prostate Cancer in January 2010 and revised the web version on May 27, 2010 to incorporate PROVENGE® (sipuleucel-T) for the treatment of advanced prostate cancer.^{1,2} These guidelines were created to assist urologists in caring for patients

with prostate cancer based on various levels of medical evidence. New to the 2010 guidelines is the recommendation of active surveillance as the only option for men with 1) low risk prostate cancer with an estimated life expectancy of less than 10 years and 2) very low risk prostate cancer with an estimated life expectancy of less than 20 years. These recommendations for active surveillance have increased the focus of urologists on guideline use, and called attention to the differences between the NCCN and the AUA guidelines.



Both guidelines originated in 1995. The missions of the NCCN and the AUA are similar in setting forth recommendations for optimal treatment based on current evidence and expert consensus. Both guideline panels advocate a multidisciplinary approach, and are composed primarily of urologists, radiation oncologists and medical oncologists. The AUA revised their Guideline for the Management of Clinically Localized Prostate Cancer in 2007 and updates were contained in the 2009 Prostate Specific Antigen (PSA) Best Practice Statement.³ The NCCN has issued updates at least annually, and considers all stages of prostate cancer including locally advanced and metastatic disease.

Choice of therapy is influenced by

▼ Continued on page 2

FROM THE Office of Education

Urological Ultrasound Education



Dr. Pat Fulgham
 Chair, Urologic Diagnostic and Therapeutic Imaging Committee
 Dallas, Texas

The AUA Office of Education continues to demonstrate its dedication to providing ultrasound education to its members. This year the AUA conducted 7 hands-on courses on urological ultrasound, and sold hundreds of self-study DVDs covering the basic principles of ultrasound, as well as site specific modules on renal, bladder, male genitalia and prostate ultrasound.

We offer urologists several opportunities to expand their skills in urological ultrasound. Our 2 weekend courses on hands-on urological ultrasound, one of which is held at AUA headquarters in Linthicum, Maryland and the other

is held in Dallas, Texas, are the most comprehensive offered. We also provide a full day hands-on course the Friday preceding the AUA meeting and 4 hands-on lab courses on Saturday, the first day of the AUA meeting.

A hands-on module on Advanced Urologic Ultrasound has been added to the 2011 AUA annual meeting in Washington, D. C. This advanced course will offer urologists the opportunity to improve their skills with Doppler ultrasound and other advanced techniques. In addition, site specific urological ultrasound training modules have been offered as part of the AUA Courses of Choice available at AUA Section meetings.

Before enrolling in an AUA ultrasound course, it is recommended that registrants purchase the Basic Urologic Ultrasound DVD and complete the online test. For a complete listing of ultrasound course offerings, visit the

course calendar on the AUA web site at www.auanet.org.

To ensure the provision of high quality patient care, the Office of Education has established a skills verification program for urological ultrasound. The AUA has funded and trained 40 instructors with expertise and interest in urological ultrasound to teach AUA

courses throughout the country. This team of instructors, also known as the National Urologic Ultrasound Faculty (NUUF), has created and delivered educational modules on renal, bladder, scrotal, transrectal and pediatric ultrasound. These modules focus not

▼ Continued on page 7

NON-PROFIT ORG.
 U.S. POSTAGE
 PAID
 PERMIT NO.95
 EASTON, PA

American Urological Association
 1000 Corporate Boulevard
 Linthicum, Maryland 21090

Hey Bob!

▼ Continued from page 1

a combination of factors, balancing the probabilities of cure based on clinical and pathological parameters, and patient estimated life expectancy, comorbidities, potential side effects and preference. Both guidelines advise the practitioner to estimate life expectancy but only the NCCN guidelines provide specific instructions and specify adjustment based on patient quartile of health. Bone scans and pelvic computerized tomography (CT) are incorporated in the staging evaluation in both guidelines.

According to the AUA guideline these staging studies are unnecessary in low risk cases, defined as PSA 10 ng/ml or less, cT1-2a disease and absence of Gleason score 4 or 5. However, bone scans should be considered in patients with PSA greater than 20 ng/ml, history or examination suggestive of bony involvement, Gleason score 8 or greater, or clinical stage T3 or greater. CT or magnetic resonance imaging (MRI) should be considered in men with PSA greater than 20 ng/ml, Gleason score 8 or greater, or locally advanced disease.

“Both guidelines advise the practitioner to estimate life expectancy but only the NCCN guidelines provide specific instructions and specify adjustment based on patient quartile of health.”

In contrast, the NCCN recommends determining if life expectancy exceeds 5 years before considering imaging. Bone scans are recommended for patients with T1-T2 disease, PSA greater than 20 ng/ml and Gleason score 8 or greater, those with T3, T4 disease or those who are symptomatic. Pelvic CT or MRI is recommended for patients with T3-T4 disease or T1-T2 disease with a nomogram probability of lymph node involvement greater than 20%. In all other patients no additional imaging is recommended.

Once staging is completed, patients are placed into risk stratification groups. The AUA guideline was written for clinically localized disease, and so the risk strata discussed are low, intermediate and high risk based on PSA, Gleason score and clinical T stage. The NCCN guidelines risk strata differ from those of the AUA in 3 ways.

1) T2c is considered intermediate risk in the NCCN guidelines but high risk in the AUA guideline. 2) Locally advanced, very high risk and metastatic are included in the NCCN guidelines. 3) The 2010 NCCN guidelines include the new risk category of very low risk.

The very low risk category is based on a modification of the Epstein criteria for clinically insignificant prostate cancer. To qualify as very low risk, specific criteria must be fulfilled including T1c, Gleason score 6 or less, PSA less than 10 ng/ml, fewer than 3 posi-

tive biopsy cores, 50% or less cancer in each core and PSA density less than 0.15 ng/ml/gm. For the first time active surveillance is the only option recommended for men in this category whose life expectancy is less than 20 years. Active surveillance is also the only recommendation for men with low risk prostate cancer whose estimated life expectancy is less than 10 years.

In-depth counseling must highlight the pros and cons of this option. Disadvantages, such as the chance of missed opportunity for cure, increased anxiety of living with untreated can-

cer, the risk that subsequent treatment may be more complex with increased side effects and nerve sparing at subsequent prostatectomy may be more difficult, must be discussed. Similarly the benefits must be reviewed, such as the avoidance of treatment related side effects from definitive therapy that may not be necessary, as with small indolent cancers. Concerns that men with prostate cancer are being over treated, especially older men with favorable prostate cancer, in addition to the

▼ Continued on page 3


IN THE TREATMENT OF SYMPTOMATIC BPH*

RAPID RELIEF

THAT KEEPS HIM GOING

Rapid BPH symptom relief starts in 3 to 4 days^{1,2}

- A majority of patients achieved at least a 3-point improvement in IPSS[†] total score³
- Significant improvements in total IPSS at all time points studied ($P < 0.0001$)^{1,2}



*RAPAFLO® is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). RAPAFLO® is not indicated for the treatment of hypertension.

[†]International Prostate Symptom Score

References: 1. RAPAFLO® (silodosin) Capsules full Prescribing Information. 2. Marks LS, Gittelman MC, Hill LA, et al. Rapid efficacy of the highly selective α_{1A} -adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. *J Urol.* 2009;181:2634-2640. 3. Data on file, Watson Laboratories, Inc. 4. Marks LS, Gittelman MC, Hill LA, et al. Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month open-label extension study. *Urology.* 2009;74:1318-1322. 5. Marks LS. Reply to editorial comment. *Urology.* 2009;74:1323-1324. Models are for illustrative purposes only.

Watson 

© 2010, Watson Pharma, Inc., Morristown, NJ 07960. All rights reserved.

06317 1/10

Hey Bob!

▼ Continued from page 2

prostate cancer specific mortality results from American and European randomized screening studies, have driven the NCCN to make these recommendations.^{5,6}

The AUA guideline lists active surveillance as an option for all patients but it does not recommend active surveillance for any specific group. However, the guideline emphasizes that patients with high grade tumors are not suitable candidates given the

high recurrence rates and worse survival. Both guidelines state that active surveillance entails actively monitoring the course of the disease with the expectation of intervention for obvious biochemical and/or evidence of histopathological progression. However, the NCCN defines specific progression parameters as Gleason grade 4 or 5 on repeat biopsy, prostate cancer in a greater number of cores or occupying a greater extent of the biopsy tissue, or PSA doubling time less than 3 years.

Patients requiring intervention can

be treated with various modalities. According to the AUA guideline brachytherapy is listed as an option for all risk strata, whereas the NCCN recommends brachytherapy as an option only in cases of low risk or intermediate risk disease. The NCCN guidelines also specify the regimen doses for monotherapy vs combination therapy. Candidates suitable to receive external beam radiation therapy and recommendations for androgen deprivation therapy to be used in those with intermediate and high risk cancers are similar in both guidelines.

Both guidelines also use the new Radiation Therapy Oncology Group-American Society for Therapeutic Radiology and Oncology-Phoenix Consensus definition of biochemical failure after radiation therapy. However, NCCN guidelines require a minimum of 75 Gy radiation for monotherapy, and daily image guided radiation therapy is mandatory for radiation doses greater than 78 Gy. Patients with low risk cancers and 10-year or longer life expectancy should not



▼ Continued on page 4

Sustained relief for up to 1 year

- Significant improvement in total IPSS and irritative and obstructive IPSS subscores^{3,4}
 - Patients continuing RAPAFLOR[®] therapy experienced additional improvements in IPSS scores over the 9-month uncontrolled, open-label period^{3,4}
 - Patients continuing RAPAFLOR[®] therapy experienced an ~9-point overall reduction in IPSS total score over 52 weeks⁵

Convenient dosing regimen

- One 8-mg capsule taken once daily with a meal¹

**Changes in IPSS Over 52 Weeks^{5†}**

[†]Patients received RAPAFLOR[®] for 12 weeks in the double-blind controlled trials and for 40 weeks in the uncontrolled, open-label phase.

Important Safety Information

RAPAFLOR[®] is contraindicated in patients with severe renal impairment (CCr <30 mL/min), severe hepatic impairment (Child-Pugh score ≥10), and with use of strong CYP3A4 inhibitors.

Postural hypotension with or without symptoms (eg, dizziness) may develop when beginning treatment with RAPAFLOR[®]. As with all alpha-blockers, there is a potential for syncope. Patients should be warned of the possible occurrences of such events and should avoid situations where injury could result. RAPAFLOR[®] should be used with caution in patients with moderate renal impairment. Patients should be assessed to rule out the presence of prostate cancer prior to starting treatment with RAPAFLOR[®]. Patients planning cataract surgery should inform their ophthalmologist that they are taking RAPAFLOR[®].

The most common side effects are retrograde ejaculation, dizziness, diarrhea, orthostatic hypotension, headache, nasopharyngitis, and nasal congestion.

Please see brief summary of full Prescribing Information on adjacent page.

For more information,
please visit www.rapaflo.com

RAPAFLOR[®] 8mg
(silodosin) capsules
READY. SET. GO.

Hey Bob!

▼ Continued from page 3

receive pelvic lymph node radiation or androgen deprivation therapy. Furthermore, NCCN guidelines state that neither proton therapy nor cryotherapy is recommended as primary treatment except in a clinical trial.

Radical prostatectomy with or without pelvic lymph node dissection via the open or robotic assisted approach is the surgical treatment of choice for men with low, intermediate and selected high risk cancers. Suitable candidates for pelvic lymph node dis-

section differ between the guidelines. The AUA guideline states that the procedure may not be necessary for clinically localized prostate cancer if PSA is less than 10 ng/ml and Gleason score is 6 or less, although it emphasizes that patients with higher risk disease would benefit.

The decision to perform pelvic lymph node dissection should be guided by the probability of nodal metastases according to NCCN guidelines. The NCCN panel chose a 2% cutoff based on a nomogram, thereby avoiding 47.7% of pelvic lymph node dissections at a cost of missing 12.1%

of positive lymph nodes. The NCCN also specifies that only an extended technique should be performed.

Lastly, the definition of biochemical recurrence differs between the guidelines. The AUA guideline defines biochemical recurrence as an initial PSA of 0.2 ng/ml or greater followed by a subsequent confirmatory PSA of 0.2 ng/ml or greater. This definition is in contrast to the NCCN definition of either failure of PSA to decrease to an undetectable level or a detectable PSA that increases on 2 subsequent

▼ Continued on page 5

RAPAFLO®

(sildenafil) capsules

BRIEF SUMMARY

For full Prescribing Information, see package insert.

INDICATIONS AND USAGE

RAPAFLO, a selective alpha-1 adrenergic receptor antagonist, is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). RAPAFLO is not indicated for the treatment of hypertension.

CONTRAINDICATIONS

- Severe renal impairment (CCr < 30 mL/min)
- Severe hepatic impairment (Child-Pugh score ≥ 10)
- Concomitant administration with strong Cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ketoconazole, clarithromycin, itraconazole, ritonavir) [see Drug Interactions]

WARNINGS AND PRECAUTIONS

Orthostatic Effects

Postural hypotension, with or without symptoms (e.g., dizziness) may develop when beginning RAPAFLO treatment. As with other alpha-blockers, there is potential for syncope. Patients should be cautioned about driving, operating machinery, or performing hazardous tasks when initiating therapy [see Adverse Reactions and Use in Specific Populations].

Renal Impairment

In a clinical pharmacology study, plasma concentrations (AUC and C_{max}) of sildenafil were approximately three times higher in subjects with moderate renal impairment compared with subjects with normal renal function, while half-lives of sildenafil doubled in duration. The dose of RAPAFLO should be reduced to 4 mg in patients with moderate renal impairment. Exercise caution and monitor such patients for adverse events [see Use in Specific Populations]. RAPAFLO is contraindicated in patients with severe renal impairment [see Contraindications].

Hepatic Impairment

RAPAFLO has not been tested in patients with severe hepatic impairment, and therefore, should not be prescribed to such patients [see Contraindications and Use in Specific Populations].

Pharmacokinetic Drug-Drug Interactions

In a drug interaction study, co-administration of a single 8 mg dose of RAPAFLO with 400 mg ketoconazole, a strong CYP3A4 inhibitor, caused a 3.8-fold increase in maximum plasma sildenafil concentrations and 3.2-fold increase in sildenafil exposure (i.e., AUC). Concomitant use of ketoconazole or other strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, ritonavir) is therefore contraindicated [see Drug Interactions].

Pharmacodynamic Drug-Drug Interactions

The pharmacodynamic interactions between sildenafil and other alpha-blockers have not been determined. However, interactions may be expected, and RAPAFLO should not be used in combination with other alpha-blockers [see Drug Interactions].

A specific pharmacodynamic interaction study between sildenafil and antihypertensive agents has not been performed. However, patients in the Phase 3 clinical studies taking concomitant antihypertensive medications with RAPAFLO did not experience a significant increase in the incidence of syncope, dizziness, or orthostasis. Nevertheless, exercise caution during concomitant use with antihypertensives and monitor patients for possible adverse events [see Adverse Reactions and Drug Interactions].

Caution is also advised when alpha-adrenergic blocking agents including RAPAFLO are co-administered with PDE5 inhibitors. Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. Concomitant use of these two drug classes can potentially cause symptomatic hypotension [see Drug Interactions].

Carcinoma of the Prostate

Carcinoma of the prostate and BPH cause many of the same symptoms. These two diseases frequently co-exist. Therefore, patients thought to have BPH should be examined prior to starting therapy with RAPAFLO to rule out the presence of carcinoma of the prostate.

Intraoperative Floppy Iris Syndrome

Intraoperative Floppy Iris Syndrome has been observed during cataract surgery in some patients on alpha-1 blockers or previously treated with alpha-1 blockers. This variant of small pupil syndrome is characterized by the combination of a flaccid iris that billows in response to intraoperative irrigation currents; progressive intraoperative miosis despite preoperative dilation with standard mydriatic drugs; and potential prolapse of the iris toward the phacemulsification incisions. Patients planning cataract surgery should be told to inform their ophthalmologist that they are taking RAPAFLO [see Adverse Reactions].

Laboratory Test Interactions

No laboratory test interactions were observed during clinical evaluations. Treatment with RAPAFLO for up to 52 weeks had no significant effect on prostate-specific antigen (PSA).

ADVERSE REACTIONS

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

In U.S. clinical trials, 897 patients with BPH were exposed to 8 mg RAPAFLO daily. This includes 486 patients exposed for 6 months and 168 patients exposed for 1 year. The population was 44 to 87 years of age, and predominantly Caucasian. Of these patients, 42.8% were 65 years of age or older and 10.7% were 75 years of age or older.

In double-blind, placebo controlled, 12-week clinical trials, 466 patients were administered RAPAFLO and 457 patients were administered placebo. At least one treatment-emergent adverse reaction was reported by 55.2% of RAPAFLO treated patients (36.8% for placebo treated). The majority (72.1%) of adverse reactions for the RAPAFLO treated patients (59.8% for placebo treated) were qualified by the investigator as mild. A total of 6.4% of RAPAFLO treated patients (2.2% for placebo treated) discontinued therapy due to an adverse reaction (treatment-emergent), the most common reaction being retrograde ejaculation (2.8%) for RAPAFLO treated patients. Retrograde ejaculation is reversible upon discontinuation of treatment.

Adverse Reactions observed in at least 2% of patients:

The incidence of treatment-emergent adverse reactions listed in the following table were derived from two 12-week, multicenter, double-blind, placebo-controlled clinical studies of RAPAFLO 8 mg daily in BPH patients. Adverse reactions that occurred in at least 2% of patients treated with RAPAFLO and more frequently than with placebo are shown in Table 1.

Table 1 Adverse Reactions Occurring in ≥ 2% of Patients in 12-week, Placebo-Controlled Clinical Trials

Adverse Reactions	RAPAFLO N = 466 n (%)	Placebo N = 457 n (%)
Retrograde Ejaculation	131 (28.1)	5 (1.1)
Dizziness	15 (3.2)	5 (1.1)
Diarrhea	12 (2.6)	6 (1.3)
Orthostatic Hypotension	12 (2.6)	7 (1.5)
Headache	11 (2.4)	4 (0.9)
Nasopharyngitis	11 (2.4)	10 (2.2)
Nasal Congestion	10 (2.1)	1 (0.2)

In the two 12-week, placebo-controlled clinical trials, the following adverse events were reported by between 1% and 2% of patients receiving RAPAFLO and occurred more frequently than with placebo: insomnia, PSA increased, sinusitis, abdominal pain, asthenia, and rhinorrhea. One case of syncope in a patient taking prazosin concomitantly and one case of priapism were reported in the RAPAFLO treatment group.

In a 9-month open-label safety study of RAPAFLO, one case of Intraoperative Floppy Iris Syndrome (IFIS) was reported.

Postmarketing Experience

The following adverse reactions have been identified during post approval use of sildenafil. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:

Skin and subcutaneous tissue disorders: toxic skin eruption, purpura

Hepatobiliary disorders: jaundice, impaired hepatic function associated with increased transaminase values

DRUG INTERACTIONS

Moderate and Strong CYP3A4 Inhibitors

In a clinical metabolic inhibition study, a 3.8-fold increase in sildenafil maximum plasma concentrations and 3.2-fold increase in sildenafil exposure were observed with concurrent administration of a strong CYP3A4 inhibitor, 400 mg ketoconazole. Use of strong CYP3A4 inhibitors such as itraconazole or ritonavir may cause plasma concentrations of sildenafil to increase. Concomitant administration of strong CYP3A4 inhibitors and RAPAFLO is contraindicated [see Contraindications and Warnings and Precautions].

The effect of moderate CYP3A4 inhibitors on the pharmacokinetics of sildenafil has not been evaluated. Concomitant administration with moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin, verapamil) may increase concentration of RAPAFLO. Exercise caution and monitor patients for adverse events when co-administering RAPAFLO with moderate CYP3A4 inhibitors.

Strong P-glycoprotein (P-gp) Inhibitors

In vitro studies indicated that sildenafil is a P-gp substrate. Ketoconazole, a CYP3A4 inhibitor that also inhibits P-gp, caused significant increase in exposure to sildenafil. Inhibition of P-gp may lead to increased sildenafil concentration. RAPAFLO is therefore not recommended in patients taking strong P-gp inhibitors such as cyclosporine.

Alpha-Blockers

The pharmacodynamic interactions between sildenafil and other alpha-blockers have not been determined. However, interactions may be expected, and RAPAFLO should not be used in combination with other alpha-blockers [see Warnings and Precautions].

Digoxin

Co-administration of RAPAFLO and digoxin 0.25 mg/day for 7 days was evaluated in a clinical trial in 16 healthy males, aged 18 to 45 years. Concomitant administration of RAPAFLO and digoxin did not significantly alter the steady state pharmacokinetics of digoxin. No dose adjustment is required.

PDE5 Inhibitors

Co-administration of RAPAFLO with a single dose of 100 mg sildenafil or 20 mg tadalafil was evaluated in a placebo-controlled clinical study that included 24 healthy male subjects, 45 to 78 years of age. Orthostatic vital signs were monitored in the 12-hour period following concomitant dosing. During this period, the total number of positive orthostatic test results was greater in the group receiving RAPAFLO plus a PDE5 inhibitor compared with RAPAFLO alone. No events of symptomatic orthostasis or dizziness were reported in subjects receiving RAPAFLO with a PDE5 inhibitor.

Other Concomitant Drug Therapy

Antihypertensives

The pharmacodynamic interactions between sildenafil and antihypertensives have not been rigorously investigated in a clinical study. However, approximately one-third of the patients in clinical studies used concomitant antihypertensive medications with RAPAFLO. The incidence of dizziness and orthostatic hypotension in these patients was higher than in the general sildenafil population (4.6% versus 3.8% and 3.4% versus 3.2%, respectively). Exercise caution during concomitant use with antihypertensives and monitor patients for possible adverse events [see Warnings and Precautions].

Metabolic Interactions

In vitro data indicate that sildenafil does not have the potential to inhibit or induce cytochrome P450 enzyme systems.

Food Interactions

The effect of a moderate fat, moderate calorie meal on sildenafil pharmacokinetics was variable and decreased sildenafil maximum plasma concentration (C_{max}) by approximately 18-43% and exposure (AUC) by 4-49% across three different studies. Safety and efficacy clinical trials for RAPAFLO were always conducted in the presence of food intake. Patients should be instructed to take sildenafil with a meal to reduce risk of adverse events.

USE IN SPECIFIC POPULATIONS

Pregnancy

Pregnancy Category B. RAPAFLO is not indicated for use in women.

An embryo/fetal study in rabbits showed decreased maternal body weight at 200 mg/kg/day (approximately 13-25 times the maximum recommended human exposure or MRHE of sildenafil via AUC). No statistically significant teratogenicity was observed at this dose.

Sildenafil was not teratogenic when administered to pregnant rats during organogenesis at 1000 mg/kg/day (estimated to be approximately 20 times the MRHE). No maternal or fetal effects were observed at this dose. Rats and rabbits do not produce glucuronidated sildenafil, which is present in human serum at approximately 4 times the level of circulating sildenafil and which has similar pharmacological activity to sildenafil.

No effects on physical or behavioral development of offspring were observed when rats were treated during pregnancy and lactation at up to 300 mg/kg/day.

Pediatric Use

RAPAFLO is not indicated for use in pediatric patients. Safety and effectiveness in pediatric patients have not been established.

Geriatric Use

In double-blind, placebo-controlled, 12-week clinical studies of RAPAFLO, 259 (55.6%) were under 65 years of age, 207 (44.4%) patients were 65 years of age and over, while 60 (12.9%) patients were 75 years of age and over. Orthostatic hypotension was reported in 2.3% of RAPAFLO patients < 65 years of age (1.2% for placebo), 2.9% of RAPAFLO patients ≥ 65 years of age (1.9% for placebo), and 5.0% of patients ≥ 75 years of age (0% for placebo). There were otherwise no significant differences in safety or effectiveness between older and younger patients.

Renal Impairment

The effect of renal impairment on sildenafil pharmacokinetics was evaluated in a single dose study of six male patients with moderate renal impairment and seven male subjects with normal renal function. Plasma concentrations of sildenafil were approximately three times higher in subjects with moderate renal impairment compared with subjects with normal renal function.

RAPAFLO should be reduced to 4 mg per day in patients with moderate renal impairment. Exercise caution and monitor patients for adverse events.

RAPAFLO has not been studied in patients with severe renal impairment. RAPAFLO is contraindicated in patients with severe renal impairment [see Contraindications and Warnings and Precautions].

Hepatic Impairment

In a study comparing nine male patients with moderate hepatic impairment (Child-Pugh scores 7 to 9), to nine healthy male subjects, the single dose pharmacokinetics of sildenafil were not significantly altered in patients with hepatic impairment. No dosing adjustment is required in patients with mild or moderate hepatic impairment.

RAPAFLO has not been studied in patients with severe hepatic impairment. RAPAFLO is contraindicated in patients with severe hepatic impairment [see Contraindications and Warnings and Precautions].

OVERDOSAGE

RAPAFLO was evaluated at doses of up to 48 mg/day in healthy male subjects. The dose-limiting adverse event was postural hypotension.

Should overdose of RAPAFLO lead to hypotension, support of the cardiovascular system is of first importance. Restoration of blood pressure and normalization of heart rate may be accomplished by maintaining the patient in the supine position. If this measure is inadequate, administration of intravenous fluid should be considered. If necessary, vasopressors could be used, and renal function should be monitored and supported as needed. Dialysis is unlikely to be of significant benefit since sildenafil is highly (97%) protein bound.

Watson

Manufactured by: Watson Laboratories, Inc., Corona, CA 92688 USA
Distributed by: Watson Pharma, Inc., Morristown, NJ 07962 USA

Under license from: Kissei Pharmaceutical Co., Ltd., Nagano, Japan

Address medical inquiries to: WATSON Medical Communications, P.O. Box 1953, Morristown, NJ 07962-1953
800-272-5252

For additional information see:

www.rapaflo.com

or call 1-866-RAPAFLO (727-2356)

Rx Only Revised: November 2009

173761-2 S1109

AUA News

November 2010

Volume 15–Number 11

EDITOR IN CHIEF

Robert C. Flanigan, M.D.
Maywood, Illinois

Associate Editors

Natasha Kyprianou, M.D., Ph.D.
Lexington, Kentucky
Mark Litwin, M.D., MPH
Los Angeles, California
Jerome P. Richie, M.D.
Boston, Massachusetts
Linda D. Shortliffe, M.D.
Stanford, California
Dennis D. Venable, M.D.
Shreveport, Louisiana

Spanish Edition Editor

Antonio Puras-Baez, M.D.
Santurce, Puerto Rico

Managing Editor

Deborah F. Polly
Publications Department
American Urological Association
1000 Corporate Boulevard
Linthicum, Maryland 21090

Production

Cadmus Communications
Port City Press
1323 Greenwood Rd.
Baltimore, MD 21208

National Sales Manager

The Walchi Tauber Group
2225 Old Emmorton Road, Suite 201
Bel Air, MD 21015
Phone: 443-512-8899 ext. 101

American Urological Association

2010–2011 AUA Officers

President

Datta G. Wagle, M.D.

President Elect

Sushil Lacy, M.D.

Immediate Past President

Anton Bueschen, M.D.

Secretary Robert C. Flanigan, M.D.

Treasurer Richard A. Memo, M.D.

Historian Sakti Das, M.D.

AUA News is the official newsmagazine of the American Urological Association, located at 1000 Corporate Blvd., Linthicum, MD 21090, and is a function of the AUA Education and Research, Inc. AUA News is published 12 times a year by the American Urological Association. Copyright © 2010 by American Urological Association Education and Research, Inc.. No part of this publication may be reproduced in any form or language without written permission from the publisher. Published free of charge for AUA membership. Annual non-member subscription rates: individual \$110 (\$155 foreign); institution \$135 (\$180 foreign); industry \$65 (\$135 foreign). U.S. POSTMASTER: Send address changes to AUA News, American Urological Association, 1000 Corporate Blvd., Linthicum, MD 21090. Library of Congress ISSN: 1088-7350. All correspondence on editorial matters should be addressed to: Managing Editor, American Urological Association, 1000 Corporate Boulevard, Linthicum, MD 21090

Disclaimer: The statements and opinions contained in the articles in AUA News are solely those of the individual authors and contributors and not of the American Urological Association. The appearance of advertisements in AUA News is not a warranty, endorsement or approval of the products or services advertised or of their effectiveness, quality or safety. The content of this publication may contain discussion of off-label uses of some of the agents mentioned. Please consult the prescribing information for full disclosures of approved uses. The American Urological Association disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.

Hey Bob!

▼ Continued from page 4

measurements.

The NCCN panel held an interim update teleconference in May 2010 to review the Food and Drug Administration approval of the immunotherapeutic agent sipuleucel-T for the treatment of advanced prostate cancer. The panel discussed the 2 phase 3 trials published for asymptomatic or minimally symptomatic, metastatic, castration recurrent prostate cancer.^{7,8} Median survival was improved by 4 months and a 22% reduction in the risk of death from prostate cancer was reported for sipuleucel-T vs placebo. Based on these results the panel supported inclusion of sipuleucel-T for systemic salvage therapy in patients with ECOG (Eastern Cooperative Oncology Group) performance status 0-1, estimated life expectancy greater than 6 months, no visceral disease and no or minimal symptoms.

The 2 guidelines are more similar than different. The NCCN guidelines are more inclusive and more detailed. Both guidelines assist the clinician and patient in choosing therapy using evidence-based medicine, and acknowledge that therapy is determined on an individual basis.

1. Mohler J, Bahnson RR, Boston B et al: NCCN clinical practice guidelines in oncology: prostate cancer. *J Natl Compr Canc Netw* 2010; **8**: 162.
2. NCCN Clinical Practice Guidelines in Oncology. Available at http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf. Accessed June 23, 2010.
3. American Urological Association: Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update. Available at <http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/proscan07/content.pdf>. Accessed June 23, 2010.
4. Greene KL, Albertsen PC, Babaian RJ et al: Prostate specific antigen best practice statement: 2009 update. *J Urol* 2009; **182**: 2232.
5. Andriole GL, Crawford ED, Grubb RL 3rd et al: Mortality results from a randomized prostate-cancer screening trial. *N Engl J Med* 2009; **360**: 1310.
6. Schröder FH, Hugosson J, Roobol MJ et al: Screening and prostate-cancer mortality in a randomized European study. *N Engl J Med* 2009; **360**: 1320.
7. Small EJ, Schellhammer PF, Higano CS et al: Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC 8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. *J Clin Oncol* 2006; **24**: 3089.
8. Kantoff PW, Higano CS, Shore ND et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *N Engl J Med* 2010; **363**: 411.

AUA Guideline

Dr. J. Brantley Thrasher
AUA Board of Directors, South Central Section
Representative
Kansas City, Kansas

Dr. Ian M. Thompson
San Antonio, Texas

Dr. John B. Forrest
AUA Practice Guidelines Committee Chair
Tulsa, Oklahoma

We appreciate the efforts of Drs. Seixas-Mikelus and Mohler to outline the differences between the NCCN and the AUA prostate cancer guidelines. However, it is important to provide potential reasons for the differences in the recommendations between the documents.


It should be noted that both guidelines were created using different methodologies. The AUA guideline was published in 2007. The prostate

cancer literature review panel surveyed all peer reviewed studies on that topic since publication of the guideline and determined that there was no need to revise or update the current document. Additionally, AUA guidelines are living documents that are reviewed annually to determine whether a guideline should be revised or a full panel reconvened and the guideline updated.

▼ Continued on page 6

ASSI® Spermatic Cord Holding Clamp™


For grasping the testicular cord through small incisions for correction of varicoceles.



Specially coated jaws can be placed into the incision around the cord



The cord can be lifted up and brought into view



ASSI.VAS47326

*Designed by Anthony J. Thomas, M.D.
Head, Section Male Infertility, Glickman Urological Institute
Cleveland Clinic Foundation, Cleveland, Ohio*

Patent Pending

assi®
ACCURATE SURGICAL & SCIENTIFIC INSTRUMENTS®
For diamond perfect performance™

accurate surgical & scientific instruments corporation
516.333.2570 fax: 516.997.4948 west coast: 800.255.9378
800.645.3569 www accuratesurgical.com

Hey Bob!

▼ Continued from page 5

The AUA Prostate Cancer Guideline Panel convened with directions from the AUA Practice Guidelines Committee to create an evidence-based document to direct practicing physicians treating clinically localized prostate cancer. Emphasis in the AUA guideline process has always been to base the conclusions and recommendations on the highest level of evidence from the literature and not on the opinions of the panel.

Although AUA guideline participants comprise an international group of prostate cancer experts in the areas of medical oncology, radiation oncology, urological oncology and outcomes research, document conclusions are based on peer reviewed articles using strict criteria for data review and extraction. The reader is encouraged to review figure 2 and the appendix in the primary guideline document, both of which demonstrate why reaching definitive conclusions regarding the best treatment for any patient was not possible after a comprehensive review of available evidence (<http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines.cfm?sub=pc>).

Given the different methodologies (highly proscriptive, evidence-based recommendations vs consensus-based recommendations), it is not surprising that there are differences in the NCCN and AUA guidelines. The AUA guideline focused on only clinical stage T1 and T2 disease with elimination of cross-contamination from T3 disease. This strict requirement eliminated some studies from consideration as well as changed the spectrum of patients considered. There are also other noteworthy differences.

Published Active Surveillance Studies						
References	No. Pts	Median Pt Age	Median Mos Followup	(%) Overall Survival	(%) Ca Specific Survival	% Remaining on Surveillance
Klotz et al ¹	450	70.3	82	78.6	97.2	70
Carter et al ²	407	66	41	98	100	59
Soloway et al ³	99	66	45	100	100	92
van den Bergh et al ⁴	616	66	47	77	100	43
Khatami et al ⁵	270	64	63	NR	100	61
van As et al ⁶	326	67	22	98	100	73
Overall	2,168	68	43	90	99.7	64

The new NCCN recommendation lists active surveillance as the only option for the patient with low risk prostate cancer whose estimated life expectancy is less than 10 years and very low risk disease with an estimated life expectancy of less than 20 years is not supported by the literature. The available studies in the literature on

“Given the different methodologies (highly proscriptive, evidence-based recommendations vs consensus-based recommendations), it is not surprising that there are differences in the NCCN and AUA guidelines.”

active surveillance are listed in the table, all of which suffer from small numbers of patients, nonrandomized design and short followup.¹⁻⁶ The AUA guideline mentions this option for patients with low risk disease but in the

absence of randomized trials comparing this option to currently available standard treatments, the panel did not believe this should be the only available recommended option.

Additionally, predictions of life expectancy spanning 2 decades are fraught with inaccuracies and potentially deny the chance for cure of a disease for which one treatment option has not proved superior to another in a randomized study. However, active surveillance has been shown in a single randomized trial, mentioned in the AUA guideline to be inferior to radical prostatectomy.⁷ Also, the AUA guideline gives weight to patient preferences. As a result, it is probably premature at this time to tell a man with a low grade tumor and whose father died of prostate cancer that he cannot opt for curative treatment.

The NCCN guidelines also do not recommend brachytherapy as an option for patients with high risk prostate cancer. While it is true that the outcomes of brachytherapy for high risk disease are poor, this could also be said of all types of treatment. In the absence of high level evidence proving this specific treatment to be inferior, the AUA Practice Guidelines Committee thought that all available options should be discussed with the high risk patient.

The NCCN considers cryotherapy and proton beam radiation experimental. These treatment options were not experimental in the AUA guideline because cryotherapy has been approved by the Food and Drug Administration as a treatment option for clinically localized prostate cancer and the efficacy of proton beam radiation appears to be similar to other forms of external beam radiation.⁸ An AUA Best Practice Policy Statement has also been published on the use of cryosurgery for

localized prostate cancer (<http://www.auanet.org/content/media/cryosurgery/08.pdf>).

Finally, the AUA Prostate Cancer Guideline Panel recommended that only the highest level of evidence in the literature, preferably randomized controlled trials, be used for future guideline updates and revisions. The AUA panel reviewed 6 years of available literature on clinically localized prostate cancer and, unfortunately, found few randomized trials for inclusion.

Given the poor level of evidence in the literature evaluating available treatment options, it is risky to make single, concrete recommendations regarding excluding any treatment from consideration or selecting a single best treatment for any given patient. While this may be unsatisfactory for patients and physicians, it accurately reflects the data. These conclusions also allow patient priorities and physician insight to determine individualized treatment and provide impetus to the development of randomized clinical trials. These studies ultimately will help determine the truly best treatment for an individual patient. ♦

1. Klotz L, Zhang L, Lam A et al: Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. *J Clin Oncol* 2010; **28**: 126.
2. Carter HB, Kettermann A, Warlick C et al: Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. *J Urol* 2007; **178**: 2359.
3. Soloway MS, Soloway CT, Williams S et al: Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience. *BJU Int* 2008; **101**: 165.
4. van den Bergh RC, Roemeling S, Roobol MJ et al: Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. *Eur Urol* 2009; **55**: 1.
5. Khatami A, Aus G, Damber JE et al: PSA doubling time predicts the outcome of active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. *Int J Cancer* 2007; **120**: 170.
6. van As NJ, Norman AR, Thomas K et al: Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. *Eur Urol* 2008; **54**: 1297.
7. Bill-Axelsson A, Holmberg L, Ruutu M et al: Radical prostatectomy versus watchful waiting in early prostate cancer *N Engl J Med* 2005; **352**: 1977.
8. Jabbari S, Weinberg VK, Shinohara K et al: Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost. *Int J Radiat Oncol Biol Phys* 2010; **76**: 36.

AUA Update Series

AVAILABLE IN THREE FORMATS

■ Online

■ Print

■ Bundle (Print and Online)

ALL New Topics for 2011—Subscribe or Renew Today!

Renew subscription online at www.AUANet.org/US11renew
call 1-866-746-4282 or e-mail fulfillment@AUAnet.org.



From the Office of Education

▼ Continued from page 1

only on the clinical aspects of scanning, but also on the physics of ultrasound, image quality, patient safety and appropriate documentation of imaging studies. The educational modules ensure that comprehensive standardized content is presented at all AUA sponsored ultrasound courses.

The key feature of our educational program in ultrasound is the verification of skills. Course participants are assessed for the ability to complete the learning objectives of each course. All participants who complete an AUA sponsored ultrasound course are eligible for AMA PRA New Procedures and Skills level 1 classification. Participants who successfully complete the posttest for a live course and a DVD module are eligible for AMA PRA level 2 classification for satisfactorily meeting all specified learning objectives. Each DVD module has an associated online didactic test available via the AUA web site.

For courses with a hands-on component, each candidate is personally evaluated by a qualified NUUF instructor. This verification of skills has the additional value of providing to third parties and hospitals a justification for granting credentials in ultrasound imaging. It should be emphasized that skills level verification does not constitute a separate certification by the AUA or any other body. Currently the

American Board of Urology certification examination includes test questions related to all forms of urological imaging including ultrasound.

As part of its ongoing mission to provide the highest quality training for urology residents, the AUA Board of Directors and the American Board of Urology have updated the Urology Core Curriculum with a section on imaging. In the updated curriculum greater emphasis has been given to the basic underlying physics of ultrasound as well as machine characteristics, interpretation of artifacts, documenta-

tion and patient safety. It is hoped that by standardizing the recommended reference materials, all residents will have a similar experience with regard to urological ultrasound training.

Urology residents who become acquainted with ultrasound early in training are more likely to perform ultrasound. Several initiatives are under way to promote a more cohesive ultrasound experience for urology residents. Some program directors have adopted the AUA Ultrasound DVDs as part of their training programs. The hands-on courses have been offered to resi-

dents in the New York Section and are popular. An objective of the NUUF, now chaired by Dr. Bruce Gilbert, is to extend ultrasound training into residency training in a more structured manner. An integrated and standardized approach to ultrasound education will ensure that urology patients continue to benefit from high quality examinations provided by their urologist.

For more information on the ultrasound DVD modules and upcoming AUA ultrasound courses, please visit the AUA web site at www.auanet.org. ♦

IN ADVANCED PROSTATE CANCER...

EVEN A SMALL AMOUNT OF ANDROGEN



CAN FUEL TUMOR GROWTH¹⁻³

References: 1. Gregory CW, Johnson RT Jr, Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. *Cancer Res.* 2001;61:2892-2898. 2. Holzbeierlein J, Lal P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. *Am J Pathol.* 2004;164(1):217-227. 3. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. *Cancer Res.* 2008;68(11):4447-4454.

 Centocor Ortho Biotech Inc.

© Centocor Ortho Biotech Inc. 2010 9/10 08ADA10027



AUA

Annual Meeting
14-19 May 2011
Washington, DC USA

OUR KNOWLEDGE.
OUR PATIENTS' LIVES.

SAVE THE DATE!

May 14-19, 2011
Washington, DC

 American
Urological
Association
Education and Research, Inc.

FROM THE *Secretary*

Quality



Dr. Robert C. Flanigan
AUA News Editor in Chief
Maywood, Illinois

Quality is a word that we hear nearly each and every day in our professional lives.

The pure and simple fact is that the initiatives to make medicine safer and more effective have continued to grow, and have captured the attention of government leaders, hospital boards of trustees, hospital administrators, physicians and other health care providers. Patients are also increasingly aware of, and have greater access to, quality data compiled for our institutions and practices.

“My appeal to you as urologists and urology caregivers is to be leaders in this area of medicine called quality improvement.”

At a recent quality forum at my institution I heard many examples of how health care professionals have successfully ended or significantly decreased some of the side effects of the procedures they do and have always accepted the idea that they must have a risk associated with them that could not be changed. This appears just not to be true. The fact is that the more carefully we look at unwanted outcomes, the more it seems that the unavoidable is actually avoidable if we can only take the steps to find ways to do so.

Another truism is that if changes to improve quality are to be successful, it will likely be because physicians, nurses and other patient care providers have a key role in examining the problems that are detected and finding structural ways to resolve them. Physicians interested in improving quality of care must not only keep current with the science of their field, but also must begin to understand how systems work, and how practice variation and human psychology impact the results of their work. As Dr. Paul Batalden said, “Every system is perfectly designed to get the results it gets.” Unfortunately this concept holds true whether these results are good or bad.

As urologists interested in quality improvement we need to look care-

fully at the enormous amounts of quality data being generated (and reported) daily by our institutions and our practices. Within that data set it is likely you will find that the rates of some adverse event at your institution (for example postoperative deep venous

thrombosis, surgical site infection etc) are higher than should be expected, higher than is experienced at institutions like your own or simply seem unacceptable to you.

What do you do next? What seems to be the best course is to gather the entire team responsible for the care of the patient (as it relates to that problem) and get out of the conference room and on to the floors and care units to see exactly what is being done,

and if it is being done reliably and consistently. Then, and perhaps only then, can the team make real changes in care patterns which may improve patient quality outcomes. My appeal to you as urologists and urology caregivers is to be leaders in this area of medicine called quality improvement. It is truly amazing what can be accomplished if we not only embrace this word, quality, but actually do something tangible to improve it. ♦

A Message from Amgen

In prostate cancer–induced bone disease, there’s a key **signal that can’t be ignored**

RANK LIGAND

RANK LIGAND

In patients with prostate cancer and bone metastases, **RANK Ligand is overexpressed by osteoblasts. Increased RANK Ligand signaling drives excessive osteoclast activity, contributing to a vicious cycle of bone destruction and tumor growth that can lead to devastating fractures and other skeletal-related events¹⁻⁵**



Do the Outcomes of Radical Prostatectomy Vary Among Surgeons?



Dr. Andrew Vickers



Dr. James Eastham

New York, New York

Answers to questions of surgeon variability are in many ways self-evident. Humans vary in their ability in any technical skill. We do not expect all surgeons to have identical results in the same way that we do not expect Mets position players to share the same batting average. Therefore, the interesting question is not whether surgeons vary but the degree to which they do so.

There is accumulating evidence that the results of radical prostatectomy vary widely among surgeons. Indeed the extent of this variation is so great as to have led to calls for radical changes in the practice of urology. By way of comparison, the lowest batting average of the 2010 Mets is 0.192 with the highest being 0.293, which is about a 50% difference. In contrast, rates of many

radical prostatectomy outcomes vary 10-fold or more across surgeons.

Variation Types

One of the first studies on surgeon variation in radical prostatectomy was conducted by Begg et al, who used SEER (Surveillance, Epidemiology and End Results)-Medicare data to examine complication rates.¹ In their first analysis they demonstrated that complications varied systematically with surgeon volume. Surgeons in the lowest 25% of annual caseload had a complication rate of 6% to 8% greater than that of surgeons in the highest 25% of surgical volume. There was also important variation within the group of highest volume surgeons, with complication rates ranging from less than 5% to more than 50%. This variation was far greater than expected by chance in that 8% of high volume surgeons had postoperative complication rates greater than the predicted 99th percentile, whereas 3% had rates below the 1st percentile.

A key aspect of this study is that 2 different types of variation were analyzed separately. The first type of variation was associated with measurable characteristics of a surgeon such as training, experience or type of institution. The second type of variation was associated with unmeasured aspects of technique, and is described as heterogeneity or extra-binomial variation.

A Message from Amgen

RANK Ligand: an essential mediator of bone destruction in patients with prostate cancer and bone metastases

Studies suggest 65%-75% of patients with advanced prostate cancer can develop bone metastases over the course of their disease⁶

Recognizing the central role of **RANK Ligand** is pivotal to understanding the underlying mechanism of bone disease in patients with prostate cancer and bone metastases.^{4,5}

What is RANK Ligand?

RANK Ligand is a protein expressed by osteoblasts, the cells responsible for bone formation. RANK Ligand promotes the differentiation, activation, and survival of bone-resorbing osteoclasts.^{1,4,7,8} In healthy bone, the body regulates RANK Ligand activity to balance bone formation and bone resorption.^{1,2}

RANK Ligand in metastatic prostate cancer

When tumor cells invade the bone microenvironment, they secrete cytokines and growth factors that stimulate osteoblasts to overexpress RANK Ligand. This increased RANK Ligand signaling disrupts the natural balance of bone remodeling by driving excessive osteoclast activity and perpetuates the vicious cycle of bone destruction and tumor growth that can lead to

devastating skeletal-related events (SREs).^{4,5} In preclinical models, data suggest that RANK Ligand may act as a signal for RANK-expressing prostate tumor cells to preferentially metastasize to bone.^{9,10}


RANK Ligand overexpression and skeletal complications

Data have shown that SREs are common in patients not treated for bone metastases from prostate cancer, with 49% (101/208) of patients experiencing an SRE within 2 years.¹¹

SREs, which include pathological fracture, palliative radiation therapy, surgery to bone, and spinal cord compression, can lead to intractable pain and impaired mobility.^{6,11}



Image courtesy of the Tel Aviv Sourasky Medical Center, www.tasmc.org.il/e/



Amgen is committed to understanding the role of **RANK Ligand** in cancer-induced bone disease. To learn more about **RANK Ligand**, please visit www.rankligandincancer.com.

1. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. *Nature*. 2003;423:337-342. 2. Hofbauer LC, Schoppert M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. *JAMA*. 2004;292:490-495. 3. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. *Cancer*. 2007;110:1860-1867. 4. Floodman GD. Mechanisms of bone metastasis. *N Engl J Med*. 2004;350:1655-1664. 5. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. *Nat Rev Cancer*. 2002;2:584-593. 6. Coleman RE. Skeletal complications of malignancy. *Cancer*. 1997;80(suppl 8):1589-1594. 7. Lacey DL, Tan HL, Lu J, et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. *Am J Pathol*. 2000;157:435-448. 8. O'Brien EA, Williams JHH, Marshall MJ. Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria. *Biochem Biophys Res Commun*. 2000;274:281-290. 9. Armstrong AP, Miller RE, Jones JC, Zhang J, Keller ET, Dougal VC. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. *Prostate*. 2008;68:92-104. 10. Dougal VC. RANKL signaling in bone physiology and cancer. *Curr Opin Support Palliat Care*. 2007;1:317-322. 11. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. *J Natl Cancer Inst*. 2004;96:879-882.

Surgical Outcomes and Surgeon Variability


▼ Continued from page 9

Indeed the wealth of articles on volume is not because researchers *prima facie* defined volume as an important predictor variable, but because the structure of databases like SEER-Medicare is such that only research on volume and not experience is possible.

Our initial study on surgeon experience included 7,765 patients treated with open radical prostatectomy at 1 of 4 United States academic centers.² After adjusting for tumor characteristics, the risk of biochemical recurrence at 5 years decreased from approximately 18% for a typical patient treated by an inexperienced surgeon (10 radical prostatectomies) to 11% for those treated by more experienced surgeons (250 cases).

This result was independently replicated using a data set of 4,702 patients with prostate cancer treated laparoscopically by 1 of 29 surgeons from 7 institutions in Europe and North America.³ The patients in the latter series were all treated after the stage shift, and there was no important association between surgeon experience and patient characteristics. Thus, it is unlikely that the findings could be explained by patient selection.

In a subgroup analysis recurrence rates for organ confined disease decreased from close to 15% for inexperienced surgeons to less than 1% for



Learning curve for open (gray) and laparoscopic (black) radical prostatectomy. Broken lines indicate 95% CI.

the most experienced surgeons with 1,500 or more prior cases.⁴ This constitutes a greater than 10-fold difference in recurrence rates across surgeons. Improving outcomes with experience is what is commonly referred to as a learning curve (see figure).

Recurrence rates differ even after adjusting for experience,⁵ that is the chance of cure can vary depending on which of 2 surgeons a patient sees even if they are similarly experienced. We have also recently studied important variation in outcomes for erectile and urinary dysfunction (unpublished data). Even within a small group of surgeons at 1 academic center rates of full potency at 1 year ranged from less than 10% to more than 50%, and uri-

nary dysfunction rates ranged from less than 5% to more than 35%.

What is to Be Done?

Gross variations in patient outcomes after radical prostatectomy are unacceptable, and steps must be taken to ensure that patients receive more uniform and high quality care. If there was similar variation in baseball some position players would be hitting 0.030, and it is hard to believe that many managers or fans would put up with such dismal performance.

The first step in improving outcomes is surely the monitoring of outcomes. Surgeons need to know how their results compare to those of their peers, which leads to an interesting

spin on the volume-outcome debate. Some have argued that volume is not a surrogate for quality. In other words, it is perfectly possible for a low volume surgeon to have good results while a high volume surgeon performs poorly.

The problem with this argument is that if you do not have volume, you will never know about outcome. We cannot be sure that a surgeon who operates on only a handful of cases per year offers effective treatment any more than we can assess whether a baseball player with only 10 lifetime at bats is a good hitter. Thus, we should insist that surgeons choosing to perform radical prostatectomy conduct a high volume of cases and we should carefully monitor their outcomes. ♦

1. Begg CB, Riedel ER, Bach PB et al: Variations in morbidity after radical prostatectomy. *N Engl J Med* 2002; **346**: 1138.
2. Vickers AJ, Bianco FJ, Serio AM et al: The surgical learning curve for prostate cancer control after radical prostatectomy. *J Natl Cancer Inst* 2007; **99**: 1171.
3. Vickers AJ, Savage CJ, Hruza M et al: The surgical learning curve for laparoscopic radical prostatectomy: a retrospective cohort study. *Lancet Oncol* 2009; **10**: 475.
4. Vickers AJ, Bianco FJ, Gonen M et al: Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. *Eur Urol* 2008; **53**: 960.
5. Bianco FJ Jr, Vickers AJ, Cronin AM et al: Variations among experienced surgeons in cancer control after open radical prostatectomy. *J Urol* 2010; **183**: 977.

Impact of Shock Wave Delivery Rate on Stone-Free Outcome and Treatment Cost




Dr. Eugene V. Kramolowsky
Richmond, Virginia

Since the 1980s extracorporeal shock wave lithotripsy (SWL) has been a standard of treatment for urinary calculi, and during the last 25 years the technique has been refined to improve effectiveness and efficiency. A recent change in technique has been to slow the rate of shock wave delivery, which has been reported to improve treatment efficacy by increasing the stone-free rate.^{1,2}

The impact of slowing the shock

wave delivery rate was evaluated in a cohort of 1,745 consecutive cases. All treatment was performed with a single lithotripter (Lithotron®) by more than 20 urologists at a freestanding urology surgery center. The procedures were standardized by the number of shocks delivered (3,000 per treatment), kV settings, imaging technique and use of general anesthesia. The evaluated treatments were divided into a fast rate (FR) of 120 shocks per minute in 872 cases and a slow rate (SR) of 60 shocks per minute in 873 cases. There was no statistical difference between the groups in terms of stone size or location in the urinary tract. The stone-free rate was



determined 4 to 6 weeks postoperatively by plain film of the abdomen.

A comparison of the stone-free rates of the FR and SR groups revealed a significantly higher rate (overall 14% increase) in all stone categories except for stones smaller than 25 cm² for the SR group (see figure). This improvement resulted in a marked decrease in the need for a second procedure (SWL or ureteroscopy) to render the patient stone-free. The second procedure rate in the FR group was 35.4% whereas it decreased to 18.2% in the

SR group.

The decrease in shock wave delivery rate resulted in an increased procedure time. Each SR procedure was 24 minutes longer than the FR procedure (50 vs 26 minutes), which resulted in fewer procedures that could be performed daily at the ambulatory surgery center.

To estimate the economic impact this change in SWL technique would have on the payer, the results were

▼ Continued on page 11

Shock Wave Delivery Rate

▼ Continued from page 10

compared using the 2009 Medicare reimbursement schedule. The increase in SR procedure time resulted in an increase in anesthesia related payments of \$28,294. However, the significant decrease in secondary procedures resulted in a payment decrease of \$264,989. Thus, there was a total estimated savings of \$236,695 with the SR technique. This change in technique resulted in savings of \$271.13 per SWL treatment. However, this estimate of decrease in payment may be understated considering 70% of these patients were privately insured, which generally indicates a higher payment schedule than Medicare.

In this study of a community general urology practice the SR technique for SWL resulted in a higher stone-free rate, which decreased the need for secondary procedures, thereby decreasing payer cost. The quality of patient care was likewise improved by decreasing the risk and morbidity associated with secondary procedures.

Slowing the SWL rate is an example of scientific research leading to a change in the practice patterns of clinical urologists, which translates into improved quality of patient care at a lower cost. ♦

Awarded best poster at annual meeting of the American Urological Association, San Francisco, California, May 29–June 3, 2010.

1. Davenport K, Minervini A, Keoghane S et al: Does rate matter? The results of a randomized controlled trial of 60 versus 120 shocks per minute for shock wave lithotripsy of renal calculi. *J Urol* 2006; **176**: 2055.
2. Chacko J, Moore M, Sankey N et al: Does a slower treatment rate impact the efficacy of extracorporeal shock wave lithotripsy for solitary kidney or ureteral stones? *J Urol* 2006; **175**: 1370.

Management of Overactive Bladder. Part II: How to Use Medications



Christopher K. Payne*
Stanford, California

In part I of this series on behavioral therapy 3 major points were emphasized. 1)

The clinical manifestation of urge incontinence is due to bladder dysfunction and behavioral/pelvic floor factors. 2) The bladder diary provides a simple, inexpensive assessment of the degree of bladder dysfunction. 3) The goals of the patient should be incorporated in the decision making process

because many nonmedical treatments are available and are often preferred.


Nevertheless, pharmacological therapy retains a primary position in the treatment of the overactive bladder (OAB), and most clinicians agree that medications, behavioral therapy and pelvic floor rehabilitation are complementary tools best used in combination. Patient goals are of great importance, and some prefer medical therapy alone while others prefer an

▼ Continued on page 12

In the treatment of symptomatic BPH with alpha-blockers*

SELECTIVITY FOR THE PROSTATE

The expression of α_{1A} receptors is much greater in BPH tissue than in non-BPH tissue¹



The α_{1A} receptor predominates in BPH tissue

- α_{1A} receptors mediate smooth muscle contraction in the prostate¹
- Uroselective alpha-blockers have a high affinity for α_{1A} receptors versus α_{1D} and α_{1B} receptors²

Learn more about α_1 -adrenergic receptor expression in BPH.

www.uroselective.com

*Benign prostatic hyperplasia

References: 1. Nasu K, Moriyama N, Kawabe K, et al. Quantification and distribution of α_1 -adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue. *Br J Pharmacol*. 1996;119:797-803. 2. Andersson KE, Lepor H, Wyllie MG. Prostatic α_1 -adrenoceptors and uroselectivity. *The Prostate*. 1997;30:202-215.

Watson

© 2009, Watson Pharma, Inc., Morristown, NJ 07960. All rights reserved. 06103 12/09

Visit

www.AUAnet.org/calendar
for information
on upcoming
educational courses.



Management of Overactive Bladder: Part II

▼ Continued from page 11

aggressive approach using all modalities together from the outset.

Similarly clinicians have different viewpoints, with some preferring to start every patient on medical therapy. The idea is that patients will more likely see early improvement, which will create confidence. On the other hand, others believe that medications should always be second line therapy because of the significant side effects that may cause patients to lose confidence if they experience a bad reaction. These different styles are best negotiated openly with the understanding that there is no single best approach.

I advocate selective use of early medical therapy and try to identify patients who are particularly good candidates for treatment with drugs. Patients with a low functional capacity (less than 150 to 200 ml) typically have more severe bladder dysfunction and those with high volume urine loss are less tolerant of the condition.

Patients with a low total 24-hour urine output are already practicing fluid restriction and have less opportunity to respond to behavioral change. Those with strong pelvic floor muscle contraction on examination have less chance of improving with pelvic floor

rehabilitation. Patients in whom OAB has a neurogenic cause are less likely to achieve and maintain complete remission. All of these groups are more likely to require medication to achieve an adequate response and, thus, early use of drug therapy is recommended.

The medications currently available for the treatment of OAB are listed with the usual dosing in the Appendix. All of the medications have a similar mechanism of blocking muscarinic cholinergic receptors in the bladder. There is little doubt that all medications are superior to placebo in reducing urgency and urge incontinence episodes.

Similarly the medications can cause anticholinergic side effects in other organ systems such as dry mouth and eyes, heartburn, constipation, blurry vision, palpitations etc. All drugs should be used with caution in patients who have associated difficulty emptying the bladder, although even documented bladder outlet obstruction is not an absolute contraindication. The newer once daily medications are consistently superior to short-acting generic oxybutynin due to the reduced incidence of adverse effects. Otherwise there is little evidence of meaningful differences among medications in efficacy or side effects. When deciding on the approach some important principles of medical therapy should be considered.

1. There is no best drug. Many insurance companies currently require that patients begin therapy with generic oxybutynin ER and I use a starting dose of 10 mg. All medications should be combined with timed voiding and urge inhibition strategies.
2. Although most patients see a response within 2 weeks, it is best to give a drug a full month before assessing response. A followup bladder diary collected while the patient is taking medication is helpful in evaluating treatment response.
3. Patients who experience improvement but are not dry should be encouraged to try a higher medication dose. Similarly those who are dry but still have a low functional capacity based on bladder diary should work on normalizing function using a combination of higher medication dose and/or behavioral techniques.
4. Before changing to a new medication the dose of the current drug should be increased until the patient experiences limiting side effects.
5. Patients who do not respond to a maximally tolerable dose of a medication can be given a trial of a different drug. However, when a patient does not respond to 2 different drugs there is a markedly lower chance that other drugs will be effective.
6. There is some evidence that patients who experience anticholinergic side effects with oral medications, particularly dry mouth, may find transdermal preparations more tolerable.
7. There is no rationale for combining standard anticholinergic medications, and titration to a maximum dose of a single agent is preferable. There is a rationale for combining the standard agents with imipramine, particularly if the patient has mixed incontinence, but this theoretical advantage must be balanced against the risk of cardiac toxicity from imipramine, which has significant arrhythmogenic properties.
8. Patients limited by side effects might still be treated on an as needed basis with 0.125 mg sublingual hyoscyamine, which has a rapid onset and short duration of effect.
9. Attention should be given to the cumulative anticholinergic load and the risk of central nervous system (CNS) side effects that can be significant for patients on multiple

medications. While the evidence is inadequate, theoretical arguments can be made for the use of trospium (a quaternary amine that should not cross the blood-brain barrier), darifenacin (M3 over M1 receptor selectivity limiting CNS toxicity) and solifenacin (a large molecule less likely to cross the blood-brain barrier) in such cases.

Whether drugs are used in all patients or selectively, consideration should always be given to the ultimate goal of bladder retraining. Patients who become completely continent with good capacity on the voiding diary probably have approximately a 50% chance of being able to go off medication and stay dry a long time. Titration off medication should be suggested after 3 to 6 months when drug therapy is successful. ♦

**Financial interest and/or other relationship with Afferent Pharmaceuticals, Allergan, AMS, Astellas, Celgene, Coloplast, Curant and Medtronic.*

Appendix

Oral products

Generic drugs:

- Oxybutynin immediate release (5 mg up to 3 times daily)
- Oxybutynin ER (5, 10 and 15 mg once daily)

Proprietary drugs:

- Oxybutynin ER (Ditropan XL® 5, 10 and 15 mg once daily)
- Tolterodine (Detrol® LA 4 mg once daily)
- Solifenacin (VESIcare® 5 and 10 mg once daily)
- Darifenacin (Enblex® 7.5 and 15 mg once daily)
- Trospium (SANCTURA XR® 60 mg daily)
- Fesoterodine (Toviaz® 4 and 8 mg once daily)

Transdermal products

- Oxybutynin patch (OXYTROL® 36 mg patch twice weekly, 3.9 mg daily)
- Oxybutynin gel (Gelnique® 10% gel 100 mg/gm, 1 mg gel daily)

Nonstandard products

- Hyoscyamine (Levsin® 0.125 mg SL as needed)
- Imipramine (Tofranil® 10 to 25 mg up to 3 times daily)

Meet me in Washington, DC!

AUA Annual Meeting 14-19 May 2011 Washington, DC USA

OUR KNOWLEDGE. OUR PATIENTS' LIVES.

Reserve Your Hotel Now
www.AUA2011.org

Do Mixed Histological Features Affect Survival Benefit of Chemotherapy for Bladder Cancer?



Dr. Edward M. Messing
Rochester, New York

Level 1 evidence indicates that cisplatin based multidrug chemotherapy regimens given before cystectomy

improve overall survival from muscle invasive urothelial cancer (UC) and significantly improve pathological down staging to stage pT0 (no cancer in the cystectomy specimen).^{1,2} However, 20% to 40% of muscle invasive UCs contain other histological types, primarily squamous cell and adenocarcinoma elements,³ and it is not known if these mixed histology (MH) cancers are as responsive as pure UC to these chemotherapy regimens.

In clinical series metastatic MH cancers respond to these chemotherapy regimens, although less well than does pure UC.^{4,5} It is not known whether MH cancers would also respond to these combination regimens in the nonmetastatic setting and, if so, how survival would be affected.

To answer these questions we performed a secondary analysis of the SWOG (Southwest Oncology Group) trial S8710/Intergroup INT0080 of neoadjuvant methotrexate, vinblastine and cisplatin (MVAC) plus radical cystectomy (RC) vs RC alone for stage cT2-4+, N any, M0 bladder UC. Tumors were classified as pure UC (236) or MH (59). More than half of the patients with MH or pure UC in each treatment arm had clinical stage cT3-4 (ie extravasically extending) cancer.

The chi-square and Fisher's exact tests were used to compare the proportions of cases down staged to pT0 with MH and those with pure UC in the MVAC plus RC and RC only arms. Cox regression models were used to estimate the effect of neoadjuvant MVAC on all cause mortality for patients with pure UC and those with MH tumors, with adjustment for age and clinical stage.

Down staging to pT0 was seen in MH and pure UCs using MVAC plus transurethral resection (TURBT) vs TURBT alone (RC only groups) (table 1). The additive down staging effect (ADE) when adjusted for stage was

almost twice as great in patients with MH cancer as in those with pure UC (tables 1 and 2).

The overall survival benefit from chemotherapy was greater in patients with MH tumors (HR 0.46, $p = 0.02$) than in those with pure UC (HR 0.90,

$p = 0.48$), and occurred equally in patients with clinical stage T2 and those with extravesical disease (tables 2 and 3). There was marginal evidence of statistical interaction between the use of neoadjuvant chemotherapy and histology status ($p = 0.09$).

The effectiveness of neoadjuvant MVAC in the MH group was not anticipated based on the limited data from series of patients with metastatic disease.^{4,5} Indeed it was our initial hypothesis that if MH cancer responded less well than pure UC to neoadjuvant chemotherapy, withholding this treat-

ment in such patients might be advisable to avoid unnecessary toxicity and prevent potentially harmful delays in performing surgery if necessary.⁶ However, while a primary purpose of neoadjuvant chemotherapy is to eradicate micrometastases because they are assessed radiographically rather than histologically and because survival rates are much poorer in patients with metastases than in those with localized disease, responses in the metastatic setting might not accurately predict

▼ Continued on page 14



The prostate cancer research of today gives us the prostate cancer survivor of tomorrow.

At UPMC, one of the largest urology research groups in the world is betting that new knowledge will break through today's therapeutic limitations. Basic research on tumor metastasis, new therapies for hormone-refractory prostate cancer, and the altered metabolism of cancer cells promise the raw materials for future progress. Translating basic observations into novel biomarkers or new clinical trials, such as efforts targeting endothelin

in advanced prostate cancer, are examples of our focus on improving clinical care. Our ongoing work with cesium as a radiation source for prostate cancer brachytherapy offers clinical efficacy with sharply reduced side effects. Innovative approaches to prostate cancer surgery have created UPMC as a destination for an expanding group of patients. We believe that a focus on new knowledge is the key to today's breakthroughs and tomorrow's survivors.

UPMC

UPMC.com | 1-800-533-UPMC

Affiliated with the **University of Pittsburgh School of Medicine**, UPMC is ranked among the nation's best hospitals by *U.S. News & World Report*.

Survival Benefit of Chemotherapy for Bladder Cancer

▼ Continued from page 13

responses in the local and regional setting.

There are numerous limitations to our study including the relatively small number of MH cancers, possible disagreement among pathologists in classifying MH status despite central histology review and the inability to determine the proportion of nonUC components in MH cancers. These limitations made it impossible for us to determine whether this proportion affects the response to MVAC. Also, we could not address whether other chemotherapy regimens now commonly used for UC (eg gemcitabine-cisplatin) are as effective as MVAC on MH tumors, or whether other mixed histologies such as micropapillary differentiation or UC plus small cell carcinoma respond similarly to MVAC as UC plus squamous or adenocarcinoma.

However despite these limitations, we believe that MH bladder cancer is at least as responsive to neoadjuvant MVAC chemotherapy as is pure UC. The presence of squamous or glandular differentiation in locally advanced bladder UC is a strong indication for the use of neoadjuvant chemotherapy before cystectomy. ◆

Awarded best poster at annual meeting of the American Urological Association, San Francisco, California, May 29–June 3, 2010.

1. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration: Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. *Eur Urol* 2005; **48**: 202.
2. Grossman HB, Natale RB, Tangen CM et al: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. *N Engl J Med* 2003; **349**: 859.
3. Wasco MJ, Daignault S, Zhang Y et al: Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection. *Urology* 2007; **70**: 69.
4. Logothetis CJ, Dexeus FH, Chong C et al: Cisplatin, cyclophosphamide and doxorubicin chemotherapy for unresectable urothelial tumors: the M.D. Anderson experience. *J Urol* 1989; **141**: 33.
5. Kastiris E, Dimopoulos MA, Antoniou N et al: The outcome of patients with advanced pure squamous or mixed squamous and transitional urothelial carcinomas following platinum-based chemotherapy. *Anticancer Res* 2006; **26**: 3865.
6. Gore JL, Lai J, Setodji CM et al: Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis. *Cancer* 2009; **115**: 988.

Table 1. Patient characteristics for treatment combinations

	Mixed Tumors		Pure UC	
	MVAC + RC	RC Alone	MVAC + RC	RC Alone
No. pts	32	27	115	121
Mean pt age	60	65	63	62
% cT3-T4a disease	59	70	59	57
% Female	31	15	14	21
% White	+91	78	96	96

Table 2. Patients with pT0 disease and those with unknown pT0 status at RC

Treatment Arm	No. Pts	No. pT0 (%)	No. pT0 Status Unknown (%)
Mixed tumors:			
MVAC + RC	32	11 (34)	4 (13)
RC alone	27	1 (4)	3 (11)
Pure UC:			
MVAC + RC	115	33 (29)	15 (13)
RC alone	121	17 (14)	7 (6)

Table 3. Estimated down staging effects

Subset	No. Pts	Contrast	% ADE*	95% CI	p Value
Mixed tumors	59	MVAC vs RC only	28	11, 44	0.004
Pure UC	236	MVAC vs RC only	15	5, 25	0.004
MVAC + RC	147	Mixed vs pure UC	6	-11, 23	0.51
RC only	148	Mixed vs pure UC	-8	-20, 3	0.27

*Directly standardized to the distribution of clinical stages among all patients in analysis.

Burning Bridges: Cavernous Nerve Resection

Drs. Parviz K. Kavoussi, Adam C. Straub, William D. Steers,* Raymond A. Costabile,† Brant Isakson and Jeffrey J. Lysiak
Charlottesville, Virginia

The increased detection of prostate cancer as well as the widespread availability of curative therapies for this and related diseases in which treatment results in neurovascular injury have produced a cohort of men with extended disease-free survival but ultimately with erectile dysfunction (ED).¹ Overall ED affects 25% of men in the United States and is associated with an impaired quality of life.²

Normal erectile function requires that several cell types and systems work in concert. This process includes neural input from the cavernous nerves (CNs) to release nitric oxide, coordinated changes in arterial endothelial and vascular smooth muscle cells (VSMCs) for vasodilation, and a cor-

pora cavernosal apparatus through which venous endothelium and vascular smooth muscle interact to trap blood. It is obvious that CNs can be injured during radical prostatectomy and chronically after radiotherapy for prostate cancer, and the more severe the degree of nerve injury the greater the chance of ED. However, the precise mechanisms of how nerve injury ultimately affects erectile function are not well understood.

Coordinated communication between endothelial cells (ECs) and VSMCs is paramount for smooth muscle cell relaxation and resulting tumescence. Myoendothelial junctions (MEJs) are cellular extensions through the internal elastic lamina (IEL) between ECs and VSMCs. At the points of cell-cell contact in the MEJ, gap junctions form pathways for the flow of signaling molecules

between the 2 cells.^{3,4} ECs cause smooth muscle relaxation by release of a number of factors including nitric oxide, prostaglandins and endothelium derived hyperpolarizing factor. There is recent evidence that endothelium derived hyperpolarizing factor requires intact MEJs for its action.

Since to our knowledge MEJs have not been described in the penile corpus cavernosum, the focus of our studies was to 1) determine if MEJs are present between ECs and smooth muscle cells in the corpus cavernosum, 2) use a genetic model of mice that lack MEJs to determine if they have normal erectile function and 3) determine if cavernous nerve resection (CNR) alters the presence of MEJs. All work was conducted in accordance with the Guiding Principles of the Care and Use of Research Animals promulgated by the University of Virginia.

Electron microscopy on murine and human corporal tissue revealed MEJs traversing the internal elastic lamina from the endothelial cell to the vascular smooth muscle cell as

well as from the vascular smooth muscle cell to the endothelial cell (fig. 1). In a genetic mouse model that lacked MEJs in other vascular beds (plasminogen activator inhibitor-1 deficient mice) electron microscopy on tissue sections of the corpus cavernosum confirmed the absence of MEJs as well.⁵ Interestingly CN electrical stimulation studies to assess erectile function revealed that unlike normal wild-type mice that have MEJs in the corporal tissue, mice lacking MEJs had a significant delay in the time to achieve tumescence, defined as time to reach maximum intracavernous pressure.

Since MEJs are important conduits for heterocellular communication, the data suggest that molecules transported across the gap junctions in the MEJs are important for normal corporal EC and smooth muscle cell signaling during the erectile response. It is also becoming increasingly clear that specific proteins can reside in the MEJ complexes. Thus, disruption of

▼ Continued on page 15

Effect of Cavernous Nerve Resection on Erectile Function

▼ Continued from page 14

their normal cellular distribution may, in turn, disrupt normal heterocellular communication.

As previously stated, injury to the cavernous nerves which may occur during prostatectomy results in ED. To determine if the MEJs in the corporal tissue are affected after CN injury, 1 group of normal wild-type mice were subjected to bilateral CNR and 1 group underwent sham operations. At postoperative week 4 electron microscopy of the cavernous tissue revealed that the bilateral CNR mice had a significant decrease in the number of MEJs, whereas sham operated mice had numbers similar to




Fig. 2. CNR results in loss of MEJs in corporal tissue. MEJs are observed in sham operated control mice (A, black arrows). CNR results in loss of MEJs in corporal tissue (B). Quantification of MEJs per 10 μ m IEL (C, 3 in each group).

those of unoperated control mice (fig. 2). It is intriguing to speculate that a possible mechanism of CN injury induced ED may be due to the loss of MEJs between ECs and VSMCs in the corporal tissue. However, at this time we do not know if the loss of MEJs is a cause of ED, the result of ED or simply correlated with ED. Studies are ongoing to answer these questions.

Regardless of the results of our ongoing studies it is clear that MEJs are present in human and mouse corporal tissue, and that their presence is directly correlated with ED. MEJs may have a pivotal role in the coordinated endothelial cell-smooth muscle cell response necessary for normal tumescence. Future studies are also aimed at investigating the presence of MEJs in other pathological states known to cause ED such as diabetes and smoking. ♦

*Financial interest and/or other relationship with Allergan, American Board of Urology, Food and Drug Administration and National Institutes of Health.

†Financial interest and/or other relationship with Allergan, Lilly, Vivus and Boehringer Ingelheim.

Awarded best poster at annual meeting of the American Urological Association, San Francisco, California, May 29–June 3, 2010.

1. Jemal A, Siegel R, Ward E et al: Cancer statistics, 2006. *CA Cancer J Clin* 2006; **56**: 106.
2. Haczynski J, Lew-Starowicz Z, Darewicz B et al: The prevalence of erectile dysfunction in men visiting outpatient clinics. *Int J Impot Res* 2006; **18**: 359.
3. Brisset AC, Isakson BE and Kwak BR: Connexins in vascular physiology and pathology. *Antioxid Redox Signal* 2009; **11**: 267.
4. de Wit C, Boettcher M and Schmidt VJ: Signaling across myoendothelial gap junctions—fact or fiction? *Cell Commun Adhes* 2008; **15**: 231.
5. Heberlein KR, Straub AC, Best AK et al: Plasminogen activator inhibitor-1 regulates myoendothelial junction formation. *Circ Res* 2010; **106**: 1092.




Fig. 1. MEJs in murine (A) and human (B) corpus cavernosal tissue (black arrows). MEJs can be formed from VSMC traversing IEL to EC as demonstrated in mouse section or conversely from EC to VSMC as demonstrated in human section.

Peyronie's Disease. Part II: Surgical Treatment Options



Dr. Laurence A. Levine*
Chicago, Illinois

Surgical reconstruction remains the gold standard for correcting deformities associated with Peyronie's disease (PD). The indications for surgical reconstruction include a stable deformity for at least 6 months and at least 1 year from the onset of symptoms. The deformity should be painless on palpation, and the ability or inability to engage in coital activity should be compromised due to the deformity and/or inadequate rigidity. Certainly patients in whom conservative therapy has failed and those with extensive plaque calcification are candidates for surgery.

Preoperative consent is critical because patients with PD are frequently unhappy and setting expectations regarding outcome can enhance postoperative satisfaction (Appendix 1). Patients should be informed that

curvature may persist or recur. I inform patients that the goal is to make the penis functionally straight, which is defined as less than 20 degrees of curvature in any direction. In addition, the length may change. Shortening appears to be more prevalent with plication than with grafting but both techniques should be presented as straightening procedures rather than as lengthening or shortening procedures.

The greatest risk of surgical correction without a prosthesis is decreased rigidity. This outcome has been reported to have a rate of at least 5% in all studies but occurs most often after grafting procedures. Several studies have examined predictors of postoperative erectile dysfunction (ED), and preoperative erectile quality appears to be the most reliable predictor.¹ Lastly, decreased penile sexual sensation has been reported but most patients who experience some sensory loss find that it recovers in the days and months after surgery.

Several surgical algorithms have been published, all of which essentially agree that when preoperative rigidity is adequate with or without phosphodiesterase type 5 (PDE5) inhibitors, a tunica plication technique is best when curvature is less than 60 degrees, there is no hourglass or hinge effect and the predicted loss of length would be less than 20% of the stretched length (Appendix 2). For those men who have more complex curvature of greater than 60 to 70 degrees or have a destabilizing hourglass, then excision or partial excision of plaque and grafting are recommended.^{2,4}

“Certainly patients in whom conservative therapy has failed and those with extensive plaque calcification are candidates for surgery.”

Multiple plication techniques have been presented during the last 40 years, starting with the Nesbit procedure. This approach involves excising a wedge of tunica on the convex side,

opposite the direction of the curvature. The defects are then closed to shorten the longer side. The Yachia procedure is a plication involving use of the Heineke-Mikulicz technique, whereby a longitudinal incision is made on the convex aspect but is closed transversely. Although this procedure is successful, it may exaggerate areas of narrowing.

No incision is necessary for the 16-dot technique, which involves use of extended Lembert applied nonabsorbable sutures on the convex aspect to shorten the convex side. The Duckett-Baskin tunica albuginea plication (my preferred approach) is accomplished with a pair of parallel transverse incisions through the longitudinal fibers without violating the circular fibers or cavernosal tissue. The space between the 2 parallel incisions is thinned to reduce the bulk of the pliated tissue. This procedure can be performed with permanent or absorbable sutures.

Multiple reports have been published in the last decade on these plication procedures, which in general provide an 85% to 100% rate of straightening and a 13% rate of postoperative

▼ Continued on page 16

Peyronie's Disease: Part II

▼ Continued from page 15

ED. Decreased sensation has been reported infrequently but ranges from 4% to 21%. The recently published recommendations from the International Consultation on Sexual Medicine (ICSM) in 2009 suggest that "there is no evidence that one surgical plication approach provides better outcomes over another but curvature correction can be expected with low risk of new ED" (Appendix 3).⁵

Historically when grafting was used, the assumption was that the entire scar needed to be excised to "get rid" of the disease. This procedure typically left large tunica defects that may have been responsible for the high rate of postoperative ED. With the advent of the incision or partial plaque excision, correction of severe deformity can be accomplished without a penile prosthesis and with a low rate of postoperative diminished rigidity in patients with good to excellent preoperative erections.

The other indications for incision or partial excision and grafting include curvature greater than 60 to 70 degrees and/or significant shaft narrowing resulting in a hinge effect. The incision and partial excision techniques involve a modified H-incision to correct the area of maximum deformity. The corners of the rectangular defect are expanded in a radial fashion to reestablish normal caliber as well as lengthen the shortened aspect of the penis.

A variety of grafts have been used including fat, dermis, fascia lata, dura mater, Dacron® and polytetrafluoroethylene. However, these materials have fallen out of favor as they often require a second incision with added morbidity or in the case of synthetic grafts increase the risk of infection and remain palpable. For autologous grafts, the preferred graft is the saphenous vein but this tissue may be useful as a future coronary graft.

Off-the-shelf products appear to have emerged as the preferred grafts, including Tutoplast® processed human pericardial graft and small intestinal submucosa (SIS). Multiple studies have been published in the last 2 decades on grafting techniques to correct PD. In general, satisfactory straightening rates range from 74% to 100%, and 5% to 53% of patients experience diminished rigidity postoperatively. More recent studies have indicated a 5% to 15% ED rate in patients who had strong preoperative

erections.⁶

Rehabilitation is strongly advised following surgical straightening, particularly with grafting.⁶ This process begins with massage and stretch therapy 2 weeks postoperatively for 5 minutes twice daily for 4 weeks. PDE5 inhibitors have been recommended in the early postoperative period to enhance nocturnal erections and thereby nourish the graft and reduce the risk of fibrotic changes to the exposed cavernosal tissue.¹ Recently postoperative external traction therapy has been demonstrated to prevent further or recover loss of length.⁷ The technique is to apply a penile traction device 2 to 4 weeks after surgery which is worn for 3 to 8 hours daily for 3 months.

For patients with PD who present with ED refractory to medical therapy, a penile prosthesis is recommended.⁸ Adequate straightening can occur simply by placing the device, and a high pressure cylinder is recommended. A significant and important advance to simplify the correction of curvature is manual modeling, which must be done with great care so as not to disrupt the corporotomies or extrude the distal tips of the prosthesis through the meatus.⁹

If there is residual curvature after modeling of more than 30 degrees, a tunica releasing incision is recommended. This procedure should be performed with no more than 35 watts of cautery power to reduce the likelihood of thermal injury to the underlying cylinders. If a tunica defect is larger than 2 cm, then applying a biograft such as pericardium or SIS is indicated to reduce the likelihood of cicatrix contracture or cylinder herniation.

Recent experience from our institution has been published on 90 consecutive inflatable penile prostheses (IPPs) placed in men with PD and drug refractory ED.¹⁰ In this series 4% of patients had satisfactory straightening with an IPP alone, 79% required only modeling, 4% had an incision and 12% had grafting over the incision. There was 1 case of infection and the mechanical failure rate for the group was 7% with a mean followup of 49 months. A nonvalidated questionnaire revealed that overall patient satisfaction was 84% but satisfaction with curvature correction was only 73%.

These results suggest that patients may find any residual curvature distressing. If the patient insists on complete straightening, he should understand that further surgical maneuvers such as incision and graft-

ing may be necessary with possible increased risks of postoperative complications.

In conclusion, PD seems to be far more prevalent than previously thought. More men are presenting with PD around the world and are seeking effective treatment options. Non-surgical therapy as discussed in part I of this series is appropriate for the patient who does not have stable disease or who declines surgery. However for those men who want the most rapid and reliable result, surgical correction remains an option. ♦

**Financial interest and/or other relationship with American Medical Systems, Coloplast, Pfizer, Auxilium and Physiomed.*

Appendix 1: Patient Consent: Set Expectations Regarding Outcome

Persistent/recurrent curvature:	Goal – "functionally straight," less than 20 degrees
	Ensure stable disease preoperatively
Change in length:	More likely shorter with plication vs grafting
Diminished rigidity:	5% or More in all studies – especially with grafting
	30% or More if suboptimal preoperative rigidity, dependent on preoperative erectile quality
Decreased sexual sensation:	Common but rarely compromises orgasm/ejaculation

Appendix 2: Surgical Algorithms

When rigidity is adequate with or without pharmacotherapy

Tunica plication techniques:

Simple curve less than 60 to 70 degrees

No hourglass or hinge effect

When length decrease is less than 20% total erect length

Incision/partial excision and grafting:

Complex curve greater than 60 to 70 degrees

Destabilizing hourglass or hinge

Penile prosthesis placement when rigidity is inadequate:

IPP alone (not Ultrex™/LGX™)

With modeling

With incision

With incision and grafting (defect greater than 2 cm)

Appendix 3: ICSM Recommendations With Regard to Surgery

- Detailed consent is imperative
 - Follow published algorithms
 - Plication for less severe deformity graded as less than 60 degrees and when borderline ED
 - Grafting reserved for severe deformity greater than 60 to 70 degrees ± hinge, normal erectile function and experienced surgical team
 - Prosthesis placement with additional maneuvers when refractory ED occurs with PD
- Levine LA, Greenfield JM and Estrada CR: Erectile dysfunction following surgical correction of Peyronie's disease and a pilot study of the use of sildenafil citrate rehabilitation for postoperative erectile dysfunction. *J Sex Med* 2005; **2**: 241.
 - Levine LA and Lenting EL: A surgical algorithm for the treatment of Peyronie's disease. *J Urol* 1997; **158**: 2149.
 - Mulhall J, Anderson M and Parker M: A surgical algorithm for men with combined Peyronie's disease and erectile dysfunction: functional and satisfaction outcomes. *J Sex Med* 2005; **2**: 132.
 - Ralph DJ: The surgical treatment of Peyronie's disease. *Eur Urol* 2006; **50**: 196.
 - Ralph D, Gonzalez-Cadavid N, Mirone V et al: The management of Peyronie's disease: evidence-based 2010 guidelines. *J Sex Med* 2010; **7**: 2359.
 - Taylor FL and Levine LA: Surgical correction of Peyronie's disease via tunica albuginea plication or partial plaque excision with pericardial graft: long-term follow up. *J Sex Med* 2008; **5**: 2221.
 - Moncada-Iribarren I, Jara J, Martinez-Salamanca JJ et al: Managing penile shortening after Peyronie's disease surgery. *J Urol*, suppl., 2007; **177**: 252, abstract 750.
 - Levine LA and Dimitriou RJ: A surgical algorithm for penile prosthesis placement in men with erectile failure and Peyronie's disease. *Int J Impot Res* 2000; **12**: 147.
 - Wilson SK and Delk JR 2nd: A new treatment for Peyronie's disease: modeling the penis over an inflatable penile prosthesis. *J Urol* 1994; **152**: 1121.
 - Levine LA, Benson J and Hoover C: Inflatable penile prosthesis placement in men with Peyronie's disease and drug-resistant erectile dysfunction: a single-center study. *J Sex Med* 2010; Epub ahead of print.



Helped over **25 million men** with ED¹

In a survey, **97% of men** with ED taking 1 of 3 oral ED medications initiated sex within 4 hours.^{1*} This is the duration of action of VIAGRA

Offers long-term **treatment satisfaction**^{2†‡}

Proven efficacy for men with ED, including those with hypertension, diabetes, or depression[‡]

Works in 30 minutes for most men, in 14 for some^{3§}

There's only one **VIAGRA**

There are plenty of reasons to prescribe VIAGRA for ED. What's yours?

*Results taken from an online survey of 772 short- and long-term patients aged 35 to 80 taking Cialis® (tadalafil), Levitra® (vardenafil HCl), or VIAGRA for erectile dysfunction (ED). Patients were asked "How soon after taking a (VIAGRA, Cialis, or Levitra) pill do you typically initiate sexual intercourse?"

†Results from an open-label, flexible-dose study with 979 patients with ED who had previously completed a double-blind trial and an open-label extension study of VIAGRA. At yearly intervals up to 4 years or at discontinuation, patients were asked if they were satisfied with their erections. Only 62 patients discontinued treatment due to insufficient response, and 11 due to adverse events. At year 4 (N=571), 96.3% said they were satisfied.

‡Data pooled from 26 flexible-dose, placebo-controlled, parallel-group, phase 2, 3, and 4 studies with 6146 patients with ED who responded to Q7 of the International Index of Erectile Function (IIEF). Patients taking VIAGRA for ED (n=3260) reported a 94% improvement from baseline in the frequency of satisfactory sexual intercourse, compared with 22% with placebo (n=2886; P<.0001). In the same data set, patients responded to Q3 (N=6144) and Q4 (N=6136), reporting an 81% improvement from baseline in the ability to penetrate (P<.0001) and a 104% improvement from baseline in the ability to maintain an erection (P<.0001), compared with 19% and 26% for placebo, respectively.¹

§Results from a double-blind phase of a placebo-controlled, fixed-dose study (VIAGRA 100 mg) of 228 patients with ED of various etiologies and degrees of severity. The study assessed onset of action (median time to erection hard enough for penetration and to erection that resulted in successful intercourse). The study included previous VIAGRA responders who took 100 mg at least 2 hours after eating. Thirty minutes postdose, 67.8% of patients taking VIAGRA 100 mg had an erection that resulted in successful intercourse versus 36.3% taking placebo. Fourteen minutes postdose, 34.8% of patients taking VIAGRA 100 mg had an erection that resulted in successful intercourse versus 22.1% taking placebo.

VIAGRA is indicated for the treatment of erectile dysfunction (ED).

Important Safety Information

The use of VIAGRA and organic nitrates in any form, at any time, is contraindicated.

Before treating ED, physicians should consider the impact of resuming sexual activity and the mild and transient vasodilatory effects of VIAGRA on blood pressure. Physicians should carefully consider whether patients with underlying cardiovascular disease or other more unusual conditions could be adversely affected by vasodilatory effects, especially in combination with sexual activity.

As there have been infrequent reports of prolonged erections lasting more than 4 hours or priapism with all ED treatments in this drug class, patients should be advised to seek immediate medical attention should these occur.

In a controlled interaction study of VIAGRA and amlodipine, the mean additional reduction in supine blood pressure was 8 mm Hg systolic and 7 mm Hg diastolic.

Physicians should advise patients of the potential for PDE5 inhibitors, including VIAGRA, to augment the blood pressure-lowering effects of alpha blockers and antihypertensive medications. In some patients concomitant administration of a PDE5 inhibitor and alpha blocker may lead to symptomatic hypotension. Patients should be stable on alpha-blocker therapy prior to initiating VIAGRA treatment and VIAGRA should be initiated at the lowest dose (25 mg).

Sudden decrease or loss of hearing has been reported in temporal association with the use of PDE5 inhibitors, including VIAGRA. Non-arteritic anterior ischemic optic neuropathy (NAION) has been reported rarely post-marketing in temporal association with the use of PDE5 inhibitors, including VIAGRA. It is not possible to determine if either of these events is related to PDE5 inhibitors or to other factors. Physicians should advise patients to stop use of PDE5 inhibitors, including VIAGRA, and seek medical attention in the event of sudden decrease of vision or hearing.

Use of VIAGRA offers no protection against sexually transmitted diseases, including the human immunodeficiency virus (HIV); therefore, physicians should consider counseling their patients about protective measures.

The most common side effects of VIAGRA were headache, flushing, and dyspepsia.

Cialis is a registered trademark of Lilly ICOS LLC; Levitra is a registered trademark of Bayer AG and is used under license by GlaxoSmithKline.

For more information, visit www.PfizerPro.com/VIAGRA.

Please see brief summary of prescribing information for VIAGRA tablets on the following pages. The blue diamond tablet shape is a registered trademark of Pfizer Inc.



HAVE YOU Read?



Dr. Carl A. Olsson
New York, New York

Kumarasamy KK, Toleman MA, Walsh TR et al: Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. *Lancet Infect Dis* 2010; 10: 597-602.

Gram-negative enterobacter organisms with resistance to carbapenems are a potential global health threat. These authors identified numerous iso-

lates of *Escherichia coli* and other Enterobacteriaceae (*Klebsiella*) containing the carbapenem resistance gene NDM-1 (New Delhi metallo-beta-lactamase-1 gene) in areas of India, Pakistan and the United Kingdom. Most of the U.K. isolates were from patients who had recently traveled to India or Pakistan, often receiving medical treatment in those countries. As of September 14 these superbug infections had been reported in Canada, Japan, France and Belgium. The first 3 cases in the United States were also reported in people who received medical care in

India or Pakistan. This information could put a real damper on tourism.

Hurst FP, Abbott KC, Raj D et al: Arteriovenous fistulas among incident hemodialysis patients in Department of Defense and Veterans Affairs facilities. *J Am Soc Nephrol* 2010; 21: 1571-1577.

In many countries other than the United States hemodialysis is initiated in a higher proportion of patients with an arteriovenous fistula (AVF) already performed and matured. Hurst et al report that the number of patients beginning hemodialysis in the U.S. in 2005 and 2006 with an AVF was shockingly low (14%). If patients had

Veterans Affairs or Department of Defense insurance the number was twice as high (27%) due to available pre-transplant kidney care and early vascular surgery consultation. Of patients with employer group insurance only 18.5% started dialysis with a mature AVF, and of those with Medicare and Medicaid the rates were even lower at 15.6% and 13%, respectively.

A Fistula First Breakthrough Coalition working with the Centers for Medicare & Medicaid Services and End Stage Renal Disease Networks is striving to increase these

▼ Continued on page 19

REFERENCES: 1. Data on File. Pfizer Inc, New York, NY. 2. McMurray JG, Feldman RA, Auerbach SM, deRiesthal H, Wilson N; for the Multicenter Study Group. Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction. *Ther Clin Risk Manag*. 2007;3:975-981. 3. Padma-Nathan H, Stecher VJ, Sweeney M, Orazem J, Tseng L-J, deRiesthal H. Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial. *Urology*. 2003;62:400-403.

Brief summary of prescribing information

VIAGRA[®]

(sildenafil citrate) tablets

INDICATION AND USAGE

VIAGRA is indicated for the treatment of erectile dysfunction.

CONTRAINDICATIONS

Consistent with its known effects on the nitric oxide/cGMP pathway (see **CLINICAL PHARMACOLOGY**), VIAGRA was shown to potentiate the hypotensive effects of nitrates, and its administration to patients who are using organic nitrates, either regularly and/or intermittently, in any form is therefore contraindicated.

After patients have taken VIAGRA, it is unknown when nitrates, if necessary, can be safely administered. Based on the pharmacokinetic profile of a single 100 mg oral dose given to healthy normal volunteers, the plasma levels of sildenafil at 24 hours post dose are approximately 2 ng/mL (compared to peak plasma levels of approximately 440 ng/mL) (see **CLINICAL PHARMACOLOGY: Pharmacokinetics and Metabolism**). In the following patients: age >65, hepatic impairment (e.g., cirrhosis), severe renal impairment (e.g., creatinine clearance <30 mL/min), and concomitant use of potent cytochrome P450 3A4 inhibitors (erythromycin), plasma levels of sildenafil at 24 hours post dose have been found to be 3 to 8 times higher than those seen in healthy volunteers. Although plasma levels of sildenafil at 24 hours post dose are much lower than at peak concentration, it is unknown whether nitrates can be safely coadministered at this time point.

VIAGRA is contraindicated in patients with a known hypersensitivity to any component of the tablet.

WARNINGS

There is a potential for cardiac risk of sexual activity in patients with preexisting cardiovascular disease. Therefore, treatments for erectile dysfunction, including VIAGRA, should not be generally used in men for whom sexual activity is inadvisable because of their underlying cardiovascular status.

VIAGRA has systemic vasodilatory properties that resulted in transient decreases in supine blood pressure in healthy volunteers (mean maximum decrease of 8.4/5.5 mmHg). (see **CLINICAL PHARMACOLOGY: Pharmacodynamics**). While this normally would be expected to be of little consequence in most patients, prior to prescribing VIAGRA, physicians should carefully consider whether their patients with underlying cardiovascular disease could be affected adversely by such vasodilatory effects, especially in combination with sexual activity.

Patients with the following underlying conditions can be particularly sensitive to the actions of vasodilators including VIAGRA – those with left ventricular outflow obstruction (e.g., aortic stenosis, idiopathic hypertrophic subaortic stenosis) and those with severely impaired autonomic control of blood pressure.

There is no controlled clinical data on the safety or efficacy of VIAGRA in the following groups; if prescribed, this should be done with caution.

- Patients who have suffered a myocardial infarction, stroke, or life-threatening arrhythmia within the last 6 months;
- Patients with resting hypotension (BP <90/50) or hypertension (BP >170/110);
- Patients with cardiac failure or coronary artery disease causing unstable angina;
- Patients with retinitis pigmentosa (a minority of these patients have genetic disorders of retinal phosphodiesterases).

Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours in duration) have been reported infrequently since market approval of VIAGRA. In the event of an erection that persists longer than 4 hours, the patient should seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency could result.

The concomitant administration of the protease inhibitor ritonavir substantially increases serum concentrations of sildenafil (11-fold increase in AUC). If VIAGRA is prescribed to patients taking ritonavir, caution should be used. Data from subjects exposed to high systemic levels of sildenafil are limited. Visual disturbances occurred more commonly at higher levels of sildenafil exposure. Decreased blood pressure, syncope, and prolonged erection were reported in some healthy volunteers exposed to high doses of sildenafil (200-800 mg). To decrease the chance of adverse events in patients taking ritonavir, a decrease in sildenafil dosage is recommended (see **Drug Interactions, ADVERSE REACTIONS AND DOSAGE AND ADMINISTRATION**).

PRECAUTIONS

General

The evaluation of erectile dysfunction should include a determination of potential underlying causes and the identification of appropriate treatment following a complete medical assessment.

Before prescribing VIAGRA, it is important to note the following:

Caution is advised when Phosphodiesterase Type 5 (PDE5) inhibitors are co-administered with alpha-blockers. PDE5 inhibitors, including VIAGRA, and alpha-adrenergic blocking agents are both vasodilators with blood pressure lowering effects. When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. In some patients, concomitant use of these two drug classes can lower blood pressure significantly (see **Drug Interactions**) leading to symptomatic hypotension (e.g., dizziness, lightheadedness, fainting).

Consideration should be given to the following:

- Patients should be stable on alpha-blocker therapy prior to initiating a PDE5 inhibitor. Patients who demonstrate hemodynamic instability on alpha-blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of PDE5 inhibitors.
- In those patients who are stable on alpha-blocker therapy, PDE5 inhibitors should be initiated at the lowest dose.
- In those patients already taking an optimized dose of a PDE5 inhibitor, alpha-blocker therapy should be initiated at the lowest dose. Stepwise increase in alpha-blocker dose may be associated with further lowering of blood pressure when taking a PDE5 inhibitor.
- Safety of combined use of PDE5 inhibitors and alpha-blockers may be affected by other variables, including intravascular volume depletion and other anti-hypertensive drugs.

VIAGRA has systemic vasodilatory properties and may augment the blood pressure lowering effect of other anti-hypertensive medications.

Patients on multiple antihypertensive medications were included in the pivotal clinical trials for VIAGRA. In a separate drug interaction study, when amlodipine, 5 mg or 10 mg, and VIAGRA, 100 mg were orally administered concomitantly to hypertensive patients mean additional blood pressure reduction of 8 mmHg systolic and 7 mmHg diastolic were noted (see **Drug Interactions**).

The safety of VIAGRA is unknown in patients with bleeding disorders and patients with active peptic ulceration. VIAGRA should be used with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie's disease), or in patients who have conditions which may predispose them to priapism (such as sickle cell anemia, multiple myeloma, or leukemia).

The safety and efficacy of combinations of VIAGRA with other treatments for erectile dysfunction have not been studied. Therefore, the use of such combinations is not recommended.

In humans, VIAGRA has no effect on bleeding time when taken alone or with aspirin. *In vitro* studies with human platelets indicate that sildenafil potentiates the antiaggregatory effect of sodium nitroprusside (a nitric oxide donor). The combination of heparin and VIAGRA had an additive effect on bleeding time in the anesthetized rabbit, but this interaction has not been studied in humans.

Information for Patients

Physicians should discuss with patients the contraindication of VIAGRA with regular and/or intermittent use of organic nitrates.

Physicians should advise patients of the potential for VIAGRA to augment the blood pressure lowering effect of alpha-blockers and anti-hypertensive medications. Concomitant administration of VIAGRA and an alpha-blocker may lead to symptomatic hypotension in some patients. Therefore, when VIAGRA is co-administered with alpha-blockers, patients should be stable on alpha-blocker therapy prior to initiating VIAGRA treatment and VIAGRA should be initiated at the lowest dose.

Physicians should discuss with patients the potential cardiac risk of sexual activity in patients with preexisting cardiovascular risk factors. Patients who experience symptoms (e.g., angina pectoris, dizziness, nausea) upon initiation of sexual activity should be advised to refrain from further activity and should discuss the episode with their physician.

Physicians should advise patients to stop use of all PDE5 inhibitors, including VIAGRA, and seek medical attention in the event of a sudden loss of vision in one or both eyes. Such an event may be a sign of non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, that has been reported rarely post-marketing in temporal association with the use of all PDE5 inhibitors. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors. Physicians should also discuss with patients the increased risk of NAION in individuals who have already experienced NAION in one eye, including whether such individuals could be adversely affected by use of vasodilators, such as PDE5 inhibitors (see **POST-MARKETING EXPERIENCE/Special Senses**).

Physicians should advise patients to stop taking PDE5 inhibitors, including VIAGRA, and seek prompt medical attention in the event of sudden decrease or loss of hearing. These events, which may be accompanied by

tinnitus and dizziness, have been reported in temporal association to the intake of PDE5 inhibitors, including VIAGRA. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors (see **ADVERSE REACTIONS, Clinical Trials and Post-Marketing Experience**).

Physicians should warn patients that prolonged erections greater than 4 hours and priapism (painful erections greater than 6 hours in duration) have been reported infrequently since market approval of VIAGRA. In the event of an erection that persists longer than 4 hours, the patient should seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency may result.

Physicians should inform patients not to take VIAGRA with other PDE5 inhibitors including REVATIO. Sildenafil is also marketed as REVATIO for the treatment of pulmonary arterial hypertension. The safety and efficacy of VIAGRA with other PDE5 inhibitors, including REVATIO, have not been studied.

The use of VIAGRA offers no protection against sexually transmitted diseases. Counseling of patients about the protective measures necessary to guard against sexually transmitted diseases, including the Human Immunodeficiency Virus (HIV), may be considered.

Drug Interactions

Effects of Other Drugs on VIAGRA

In vitro studies: Sildenafil metabolism is principally mediated by the cytochrome P450 (CYP) isoforms 3A4 (major route) and 2C9 (minor route). Therefore, inhibitors of these isoenzymes may reduce sildenafil clearance and inducers of these isoenzymes may increase sildenafil clearance.

In vivo studies: Cimetidine (800 mg), a nonspecific CYP inhibitor, caused a 56% increase in plasma sildenafil concentrations when coadministered with VIAGRA (50 mg) to healthy volunteers.

When a single 100 mg dose of VIAGRA was administered with erythromycin, a specific CYP3A4 inhibitor, at steady state (500 mg bid for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC). In addition, in a study performed in healthy male volunteers, coadministration of the HIV protease inhibitor saquinavir, also a CYP3A4 inhibitor, at steady state (1200 mg tid) with VIAGRA (100 mg single dose) resulted in a 140% increase in sildenafil C_{max} and a 210% increase in sildenafil AUC. VIAGRA had no effect on saquinavir pharmacokinetics. Stronger CYP3A4 inhibitors such as ketoconazole or itraconazole would be expected to have still greater effects, and population data from patients in clinical trials did indicate a reduction in sildenafil clearance when it was coadministered with CYP3A4 inhibitors (such as ketoconazole, erythromycin, or cimetidine) (see **DOSAGE AND ADMINISTRATION**).

In another study in healthy male volunteers, coadministration with the HIV protease inhibitor ritonavir, which is a highly potent P450 inhibitor, at steady state (500 mg bid) with VIAGRA (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil C_{max} and a 1000% (11-fold) increase in sildenafil plasma AUC. At 24 hours the plasma levels of sildenafil were still approximately 200 ng/mL, compared to approximately 5 ng/mL when sildenafil was dosed alone. This is consistent with ritonavir's marked effects on a broad range of P450 substrates. VIAGRA had no effect on ritonavir pharmacokinetics (see **DOSAGE AND ADMINISTRATION**).

Although the interaction between other protease inhibitors and sildenafil has not been studied, their concomitant use is expected to increase sildenafil levels.

In a study of healthy male volunteers, co-administration of sildenafil at steady state (80 mg t.i.d.) with endothelin receptor antagonist bosentan (a moderate inducer of CYP3A4, CYP2C9 and possibly of cytochrome P450 2C19) at steady state (125 mg b.i.d.) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil C_{max}. Concomitant administration of strong CYP3A4 inducers, such as rifampin, is expected to cause greater decreases in plasma levels of sildenafil.

Single doses of antacid (magnesium hydroxide/aluminum hydroxide) did not affect the bioavailability of VIAGRA.

Pharmacokinetic data from patients in clinical trials showed no effect on sildenafil pharmacokinetics of CYP2C9 inhibitors (such as tolbutamide, warfarin), CYP2D6 inhibitors (such as selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and related diuretics, ACE inhibitors, and calcium channel blockers. The AUC of the active metabolite, N-desmethyl sildenafil, was increased 62% by loop and potassium-sparing diuretics and 102% by non-specific beta-blockers. These effects on the metabolite are not expected to be of clinical consequence.

Effects of VIAGRA on Other Drugs

In vitro studies: Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 (IC₅₀ >150 μM). Given sildenafil peak plasma concentrations of approximately 1 μM after recommended doses, it is unlikely that VIAGRA will alter the clearance of substrates of these isoenzymes.

In vivo studies: Three double-blind, placebo-controlled, randomized, two-way crossover studies were conducted to assess the interaction of VIAGRA with doxazosin, an alpha-adrenergic blocking agent.

In the first study, a single oral dose of VIAGRA 100 mg or matching placebo was administered in a 2-period crossover design to 4 generally healthy males with benign prostatic hyperplasia (BPH). Following at least 14 consecutive daily doses of doxazosin, VIAGRA 100 mg or matching placebo was administered simultaneously with doxazosin. Following a review of the data from these first 4 subjects (details provided below), the VIAGRA dose was reduced to 25 mg. Thereafter, 17 subjects were treated with VIAGRA 25 mg or matching placebo in combination with doxazosin 4 mg (15 subjects) or doxazosin 8mg (2 subjects). The mean subject age was 66.5 years.

For the 17 subjects who received VIAGRA 25 mg and matching placebo, the placebo-subtracted mean maximum decreases from baseline (95% CI) in systolic blood pressure were as follows:

Placebo-subtracted mean maximum decrease in systolic blood pressure (mm Hg)	VIAGRA 25 mg
Supine	7.4 (-0.9, 15.7)
Standing	6.0 (-0.8, 12.8)




Figure 1: Mean Standing Systolic Blood Pressure Change from Baseline

Blood pressure was measured immediately pre-dose and at 15, 30, 45 minutes, and 1, 1.5, 2, 2.5, 3, 4, 6 and 8 hours after VIAGRA or matching placebo. Outliers were defined as subjects with a standing systolic blood pressure of <85 mmHg or a decrease from baseline in standing systolic blood pressure of >30 mmHg at one or more timepoints. There were no subjects treated with VIAGRA 25 mg who had a standing SBP < 85mmHg. There were three subjects with a decrease from baseline in standing systolic BP >30mmHg following VIAGRA 25 mg, one subject with a decrease from baseline in standing systolic BP > 30 mmHg following placebo and two subjects with a decrease from baseline in standing systolic BP > 30 mmHg following both VIAGRA and placebo. No severe adverse events potentially related to blood pressure effects were reported in this group.

Of the four subjects who received VIAGRA 100 mg in the first part of this study, a severe adverse event related to blood pressure effect was reported in one patient (postural hypotension that began 35 minutes after dosing with VIAGRA with symptoms lasting for 8 hours), and mild adverse events potentially related to blood pressure were reported in two others (dizziness, headache and fatigue at 1 hour after dosing; and dizziness, lightheadedness and nausea at 4 hours after dosing). There were no reports of syncope among these patients. For these four subjects, the placebo-subtracted mean maximum decreases from baseline in supine and standing systolic blood pressures were 14.8 mmHg and 21.5 mmHg, respectively. Two of these subjects had a standing SBP < 85mmHg. Both of these subjects were protocol violators, one due to a low baseline standing SBP, and the other due to baseline orthostatic hypotension.

In the second study, a single oral dose of VIAGRA 50 mg or matching placebo was administered in a 2-period crossover design to 20 generally healthy males with BPH. Following at least 14 consecutive days of doxazosin, VIAGRA 50mg or matching placebo was administered simultaneously with doxazosin 4 mg (17 subjects) or

Have You Read?

▼ Continued from page 18

figures by improving the stance of all insurance types, including Medicare and Medicaid, to allow pre-dialysis nephrology and vascular surgery care. These treatments are not presently covered by most insurance agencies (including Medicare and Medicaid) and, in fact, most agencies do not cover these services until renal failure actually occurs.

Chang SL, Harshman LC and Presti JC Jr: Impact of common medications on serum total prostate-specific antigen levels: analysis of the

National Health and Nutrition Examination Survey. J Clin Oncol 2010; 28: 3951-3957.

Total prostate specific antigen (PSA) determinations were correlated with the results of 10 commonly prescribed medication classes in 1,864 men 40 years old or older from the 2003 to 2006 cycles of the National Health and Nutrition Examination Survey. The 3 drug classes that revealed PSA decreases compared to nonuse were nonsteroidal anti-inflammatory drugs (NSAIDs) ($p=0.03$), statins ($p=0.01$) and thiazide diuretics ($p=0.025$). After 5 years of medication PSA decreased by 6% with NSAIDs, 13% with statins and 26%

with thiazide. If a man took statins and thiazides for 5 years PSA decreased by 36%. However, calcium channel blockers negated the effects of statins on PSA.

Kachalia A, Kaufman SR, Boothman R et al: Liability claims and costs before and after implementation of a medical error disclosure program. Ann Intern Med 2010; 153: 213-221.

This report reflects the experience of the University of Michigan Health System since they adopted a policy of full disclosure and offered compensation to victims of medical errors in 2001. The authors compared the number of new claims for compensa-

tion, number of claims compensated, time to claim resolution and claims related costs from 1995 to 2001 and from 2001 to 2006. After implementing the disclosure-with-offer program, the monthly rate of new claims decreased from 7.03 to 4.52/100,000 patient encounters (rate ratio 0.64). The average monthly rate of lawsuits decreased from 2.13 to 0.75/100,000 patient encounters and median time to claim resolution declined from 1.4 years to less than a year. Rate ratio decreased to 0.41 for average monthly cost rates from all liability, 0.41 for patient compensation and 0.39 for legal costs. These excellent results are clearly achievable given that University of Michigan Health System has a closed staff model and a captive insurance company covering the entire staff. Other large groups should strive for a similar strategy.

Vickers AJ, Cronin AM, Björk T et al: Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ 2010; 341: c4521.

Finally, an interesting article that presents a new outlook on prostate cancer screening. Vickers et al studied 1,167 patients in the Malmo Preventive Project, all of whom were 60 years old, gave blood and were followed until age 85 years. The outcome measures were prostate cancer metastasis and death from prostate cancer. The rate of screening during the study course was low in Sweden at that time. A total of 126 patients with prostate cancer were found, of whom 43 had metastatic disease or died of prostate cancer. No man had cancer detected with screening and curative therapy was attempted in only 1 patient treated with radical prostatectomy.

The PSA concentration at age 60 years was associated with prostate cancer metastasis (AUC 0.86) and death (AUC 0.90). Since PSA determinations at age 60 years were as high as greater than 20 ng/ml, the mortality rate from prostate cancer was 66% and many men had metastatic disease at the time of diagnosis, these data do not replace normal screening practices. However, these findings support the notion that if PSA at age 60 years is less than 1.0 ng/ml (83 men in this study, which is a small sampling), patients may be able to avoid further screening because there is a negligible risk of life threatening disease. ♦

with doxazosin 8 mg (3 subjects). The mean subject age in this study was 63.9 years.

Twenty subjects received VIAGRA 50 mg, but only 19 subjects received matching placebo. One patient discontinued the study prematurely due to an adverse event of hypotension following dosing with VIAGRA 50 mg. This patient had been taking minoxidil, a potent vasodilator, during the study.

For the 19 subjects who received both VIAGRA and matching placebo, the placebo-subtracted mean maximum decreases from baseline (95% CI) in systolic blood pressure were as follows:

Placebo-subtracted mean maximum decrease in systolic blood pressure (mm Hg)	VIAGRA 50 mg (95% CI)
Supine	9.08 (5.48, 12.68)
Standing	11.62 (7.34, 15.90)




Figure 2: Mean Standing Systolic Blood Pressure Change from Baseline

Blood pressure was measured after administration of VIAGRA at the same times as those specified for the first doxazosin study. There were two subjects who had a standing SBP of < 85 mmHg. In these two subjects, hypotension was reported as a moderately severe adverse event, beginning at approximately 1 hour after administration of VIAGRA 50 mg and resolving after approximately 7.5 hours. There was one subject with a decrease from baseline in standing systolic BP >30mmHg following VIAGRA 50 mg and one subject with a decrease from baseline in standing systolic BP > 30 mmHg following both VIAGRA 50 mg and placebo. There were no severe adverse events potentially related to blood pressure and no episodes of syncope reported in this study.

In the third study, a single oral dose of VIAGRA 100 mg or matching placebo was administered in a 3-period crossover design to 20 generally healthy males with BPH. In dose period 1, subjects were administered open-label doxazosin and a single dose of VIAGRA 50 mg simultaneously, after at least 14 consecutive days of doxazosin. If a subject did not successfully complete this first dosing period, he was discontinued from the study. Subjects who had successfully completed the previous doxazosin interaction study (using VIAGRA 50 mg), including no significant hemodynamic adverse events, were allowed to skip dose period 1. Treatment with doxazosin continued for at least 7 days after dose period 1. Thereafter, VIAGRA 100mg or doxazosin 8 mg was administered simultaneously with doxazosin 4 mg (14 subjects) or doxazosin 8 mg (6 subjects) in standard crossover fashion. The mean subject age in this study was 66.4 years.

Twenty-five subjects were screened. Two were discontinued after study period 1: one failed to meet pre-dose screening qualifications and the other experienced symptomatic hypotension as a moderately severe adverse event 30 minutes after dosing with open-label VIAGRA 50 mg. Of the twenty subjects who were ultimately assigned to treatment, a total of 13 subjects successfully completed dose period 1, and seven had successfully completed the previous doxazosin study (using VIAGRA 50 mg).

For the 20 subjects who received VIAGRA 100 mg and matching placebo, the placebo-subtracted mean maximum decreases from baseline (95% CI) in systolic blood pressure were as follows:

Placebo-subtracted mean maximum decrease in systolic blood pressure (mm Hg)	VIAGRA 100 mg
Supine	7.9 (4.6, 11.1)
Standing	4.3 (-1.8, 10.3)




Figure 3: Mean Standing Systolic Blood Pressure Change from Baseline

Blood pressure was measured after administration of VIAGRA at the same times as those specified for the previous doxazosin studies. There were three subjects who had a standing SBP of < 85 mmHg. All three were taking VIAGRA 100 mg, and all three reported mild adverse events at the time of reductions in standing SBP, including vasodilation and lightheadedness. There were four subjects with a decrease from baseline in standing systolic BP >30mmHg following VIAGRA 100 mg, one subject with a decrease from baseline in standing systolic BP > 30 mmHg following placebo and one subject with a decrease from baseline in standing systolic BP > 30 mmHg following both VIAGRA and placebo. While there were no severe adverse events potentially related to blood pressure reported in this study, one subject reported moderate vasodilation after both VIAGRA 50 mg and 100 mg. There were no episodes of syncope reported in this study.

When VIAGRA 100 mg oral was coadministered with amlodipine, 5 mg or 10 mg oral, to hypertensive patients, the mean additional reduction on supine blood pressure was 8 mmHg systolic and 7 mmHg diastolic.

No significant interactions were shown with tolbutamide (250 mg) or warfarin (40 mg), both of which are metabolized by CYP2C9.

VIAGRA (50 mg) did not potentiate the increase in bleeding time caused by aspirin (150 mg).

VIAGRA (50 mg) did not potentiate the hypotensive effect of alcohol in healthy volunteers with mean maximum blood alcohol levels of 0.08%.

In a study of healthy male volunteers, sildenafil (100 mg) did not affect the steady state pharmacokinetics of the HIV protease inhibitors, saquinavir and ritonavir, both of which are CYP3A4 substrates.

Sildenafil at steady state (80 mg t.i.d.) resulted in a 50% increase in AUC and a 42% increase in C_{max} of bosentan (125 mg b.i.d.).

Carcinogenesis, Mutagenesis, Impairment of Fertility

Sildenafil was not carcinogenic when administered to rats for 24 months at a dose resulting in total systemic drug exposure (AUCs) for unbound sildenafil and its major metabolite of 29- and 42-times, for male and female rats, respectively, the exposures observed in human males given the Maximum Recommended Human Dose (MRHD) of 100 mg. Sildenafil was not carcinogenic when administered to mice for 18-21 months at dosages up to the Maximum Tolerated Dose (MTD) of 10 mg/kg/day, approximately 0.6 times the MRHD on a mg/m^2 basis.

Sildenafil was negative in *in vitro* bacterial and Chinese hamster ovary cell assays to detect mutagenicity, and *in vitro* human lymphocytes and *in vivo* mouse micronucleus assays to detect clastogenicity.

There was no impairment of fertility in rats given sildenafil up to 60 mg/kg/day for 36 days to females and 102 days to males, a dose producing an AUC value of more than 25 times the human male AUC.

There was no effect on sperm motility or morphology after single 100 mg oral doses of VIAGRA in healthy volunteers.

Pregnancy, Nursing Mothers and Pediatric Use

VIAGRA is not indicated for use in newborns, children, or women.

Pregnancy Category B. No evidence of teratogenicity, embryotoxicity or fetotoxicity was observed in rats and rabbits which received up to 200 mg/kg/day during organogenesis. These doses represent, respectively, about 20 and 40 times the MRHD on a mg/m^2 basis in a 50 kg subject. In the rat pre- and postnatal development study, the no observed adverse effect dose was 30 mg/kg/day given for 36 days. In the nonpregnant rat AUC at this dose was about 20 times human AUC. There are no adequate and well-controlled studies of sildenafil in pregnant women.

Geriatric Use: Healthy elderly volunteers (65 years or over) had a reduced clearance of sildenafil (see **CLINICAL PHARMACOLOGY: Pharmacokinetics in Special Populations**). Since higher plasma levels may increase both the efficacy and incidence of adverse events, a starting dose of 25 mg should be considered (see **DOSAGE AND ADMINISTRATION**).

ADVERSE REACTIONS

CLINICAL TRIALS:

VIAGRA was administered to over 3700 patients (aged 19-87 years) during pre-marketing clinical trials worldwide. Over 550 patients were treated for longer than one year.

In placebo-controlled clinical studies, the discontinuation rate due to adverse events for VIAGRA (2.5%) was not significantly different from placebo (2.3%). The adverse events were generally transient and mild to moderate in nature.

In trials of all designs, adverse events reported by patients receiving VIAGRA were generally similar. In fixed-dose studies, the incidence of some adverse events increased with dose. The nature of the adverse events in flexible-dose studies, which more closely reflect the recommended dosage regimen, was similar to that for fixed-dose studies.

When VIAGRA was taken as recommended (on an as-needed basis) in flexible-dose, placebo-controlled clinical trials, the following adverse events were reported:

TABLE 1. ADVERSE EVENTS REPORTED BY ≥2% OF PATIENTS TREATED WITH VIAGRA AND MORE FREQUENT ON DRUG THAN PLACEBO IN PRN FLEXIBLE-DOSE PHASE III/IV STUDIES

Adverse Event	Percentage of Patients Reporting Event	
	VIAGRA N=734	PLACEBO N=725
Headache	16%	4%
Flushing	10%	1%
Dyspepsia	7%	2%
Nasal Congestion	4%	2%
Urinary Tract Infection	3%	2%
Abnormal Vision*	3%	0%
Diarrhea	3%	1%
Dizziness	2%	1%
Rash	2%	1%

*Abnormal Vision: Mild and transient, predominantly color tinge to vision, but also increased sensitivity to light or blurred vision. In these studies, only one patient discontinued due to abnormal vision.

Other adverse reactions occurred at a rate of >2%, but equally common on placebo: respiratory tract infection, back pain, flu syndrome, and arthralgia.

In fixed-dose studies, dyspepsia (17%) and abnormal vision (11%) were more common at 100 mg than at lower doses. At doses above the recommended dose range, adverse events were similar to those detailed above but generally were reported more frequently.

The following events occurred in <2% of patients in controlled clinical trials; a causal relationship to VIAGRA is uncertain. Reported events include those with a plausible relation to drug use; omitted are minor events and reports too imprecise to be meaningful:

Body as a whole: face edema, photosensitivity reaction, shock, asthenia, pain, chills, accidental fall, abdominal pain, allergic reaction, chest pain, accidental injury.

Cardiovascular: angina pectoris, AV block, migraine, syncope, tachycardia, palpitation, hypotension, postural hypotension, myocardial ischemia, cerebral thrombosis, cardiac arrest, heart failure, abnormal electrocardiogram, cardiomyopathy.

Digestive: vomiting, glossitis, colitis, dysphagia, gastritis, gastroenteritis, esophagitis, stomatitis, dry mouth, liver function tests abnormal, rectal hemorrhage, gingivitis.

Hemic and Lymphatic: anemia and leukopenia.

Metabolic and Nutritional: thirst, edema, gout, unstable diabetes, hyperglycemia, peripheral edema, hyperuricemia, hypoglycemic reaction, hypernatremia.

Musculoskeletal: arthritis, arthrosis, myalgia, tendon rupture, tenosynovitis, bone pain, myasthenia, synovitis.

Nervous: ataxia, hypertonia, neuralgia, neuropathy, paresthesia, tremor, vertigo, depression, insomnia, somnolence, abnormal dreams, reflexes decreased, hypesthesia.

Respiratory: asthma, dyspnea, laryngitis, pharyngitis, sinusitis, bronchitis, sputum increased, cough increased.

Skin and Appendages: urticaria, herpes simplex, pruritus, sweating, skin ulcer, contact dermatitis, exfoliative dermatitis.

Special Senses: sudden decrease or loss of hearing, mydriasis, conjunctivitis, photophobia, tinnitus, eye pain, ear pain, eye hemorrhage, cataract, dry eyes.

Urogenital: cystitis, nocturia, urinary frequency, breast enlargement, urinary incontinence, abnormal ejaculation, genital edema and anorgasmia.

POST-MARKETING EXPERIENCE:

Cardiovascular and cerebrovascular

Serious cardiovascular, cerebrovascular, and vascular events, including myocardial infarction, sudden cardiac death, ventricular arrhythmia, cerebrovascular hemorrhage, transient ischemic attack, hypertension, subarachnoid and intracerebral hemorrhages, and pulmonary hemorrhage have been reported post-marketing in temporal association with the use of VIAGRA. Most, but not all, of these patients had preexisting cardiovascular risk factors. Many of these events were reported to occur during or shortly after sexual activity, and a few were reported to occur shortly after the use of VIAGRA without sexual activity. Others were reported to have occurred hours to days after the use of VIAGRA and sexual activity. It is not possible to determine whether these events are related directly to VIAGRA, to sexual activity, to the patient's underlying cardiovascular disease, to a combination of these factors, or to other factors (see **WARNINGS** for further important cardiovascular information).

Special senses:

Cases of sudden decrease or loss of hearing have been reported postmarketing in temporal association with the use of PDE5 inhibitors, including VIAGRA. In some of the cases, medical conditions and other factors were reported that may have also played a role in the otologic adverse events. In many cases, medical follow-up information was limited. It is not possible to determine whether these reported events are related directly to the use of VIAGRA, to the patient's underlying risk factors for hearing loss, a combination of these factors, or to other factors (see **PRECAUTIONS, Information for Patients**).

Other events

Other events reported post-marketing to have been observed in temporal association with VIAGRA and not listed in the clinical trial adverse reactions section above include:

Nervous: seizure, seizure recurrence, anxiety, and transient global amnesia.

Urogenital: prolonged erection, priapism (see **WARNINGS**), and hematuria.

Special Senses: diplopia, temporary vision loss/decreased vision, ocular redness or bloodshot appearance, ocular burning, ocular swelling/pressure, increased intraocular pressure, retinal vascular disease or bleeding, vitreous detachment/traction, paramacular edema and epistaxis.

Non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported rarely post-marketing in temporal association with the use of phosphodiesterase type 5 (PDE5) inhibitors, including VIAGRA. Most, but not all, of these patients had underlying anatomic or vascular risk factors for developing NAION, including but not necessarily limited to: low cup to disc ratio ("crowded disc"), age over 50, diabetes, hypertension, coronary artery disease, hyperlipidemia and smoking. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors, to the patient's underlying vascular risk factors or anatomical defects, to a combination of these factors, or to other factors (see **PRECAUTIONS/Information for Patients**).

OVERDOSAGE

In studies with healthy volunteers of single doses up to 800 mg, adverse events were similar to those seen at lower doses but incidence rates and severities were increased.

In cases of overdose, standard supportive measures should be adopted as required. Renal dialysis is not expected to accelerate clearance as sildenafil is highly bound to plasma proteins and it is not eliminated in the urine.

Revised January 2010

FROM THE *Executive Director*



Michael T. Sheppard, CPA, CAE
Linthicum, Maryland

In this month's column Michael A. Pretl, Esq., AUA General Counsel, provides an update on AUA activities associated with the Red Flags Rules, which would require medical practices to implement procedures intended to reduce identify theft. The AUA is challenging implementation of the Red Flags Rules to protect the rights of all U.S. AUA members and is sharing the burden of legal expenses associated with lawsuit. The AUA Board of Directors recognizes the importance of this issue to our members and the AUA will continue to take an active role in the litigation.

Intervention to Protect AUA Members From "Red Flags Rules"



Michael A. Pretl
AUA General Counsel
Linthicum, Maryland

On August 16, 2010 the AUA joined in a motion to intervene in federal litigation seeking to block imposition of burdensome "Red Flags Rules" on all of our members. These Rules have little or nothing to do with the practice of medicine. They seem to do little to protect patients, and impose additional paperwork on busy physicians and their staff.

The Red Flags Rules were devised by the Federal Trade Commission (FTC) in 2007 to implement a 2003

expansion of the federal Fair Credit Reporting Act. The new provisions would compel financial institutions and other creditors to protect consumers against the possibility of identity theft by devising written programs encompassing effective "mitigation plans" to ensure that consumers to whom they extend credit are properly identified.

The statutory definition of "financial institutions" includes anyone who "holds a transactional account ... belonging to a consumer." It was originally believed that the Rules did not apply to health care entities as inapplicable or unnecessary in the context of the physician/patient relationship.

However, in June 2008 an FTC alert was issued to a large number of "extenders of credit" indicating that the agency had chosen to paint with a broad brush. In March 2009 the government expressly declined to exclude medical practices or other professionals from the scope of these regulatory requirements.

The American Bar Association (ABA) promptly filed suit, asserting that attorneys were not "creditors" of their clients, and that the FTC had failed to follow proper rulemaking procedures. The ABA secured an injunction from a federal judge in Washington, who ruled that lawyers and law firms should be exempted from the Rules. In May 2010 the American Medical Association (AMA) filed a similar action seeking an injunction covering and exempting physicians in private practice. However, the AMA suit applies only to its own members, and to members of its state medical societies.

Therefore, more than 20 specialty groups of physician members of the Council of Medical Specialty Societies (CMSS) have engaged counsel in Washington to represent them in seeking to intervene in the AMA proceeding to broaden the requested injunction to cover all of their members. Only an estimated 30% of AUA members currently belong to the AMA, while a larger number are members of state medical organizations.

AUA and the other specialty organizations are represented by Rob

Portman of Powers Pyles Sutter & Verville PC, an experienced Washington attorney who has long advocated for medical specialty groups (including the AUA) in such regulatory matters. The government and the AMA have consented to our intervention in the pending case. However, consideration and final resolution of the medical societies' action will likely be delayed pending resolution of a government appeal of the injunction previously granted to the ABA. The FTC has agreed not to enforce its Red Flags Rules against physicians until 90 days after a final decision in the ABA case so that the court may act in the present (medical society) litigation.

The AUA Board of Directors took prompt action and voted unanimously to authorize this intervention to protect the rights of all U.S. AUA members, many of whom would not be covered by the injunction sought by the AMA. The legal costs of the intervening societies are being shared equitably among participating CMSS members, and the AUA Board believes that the cost of this litigation is well justified. We will continue to take action, singly or in conjunction with other organizations, to resist unwarranted bureaucratic intrusion into our members' ability to serve their patients safely, effectively and compassionately. Additional updates will be provided in future issues of *AUANews*. ♦

HEALTH POLICY / *Government Affairs*

Health Policy: The Power of Teamwork



Dr. Steven M. Schlossberg
Chair, Health Policy
New Haven, Connecticut

Recently, I had the pleasure of witnessing true teamwork in action with the introduction of a bill in the U.S. Senate and U.S. House of Representatives to improve federal efforts to coordinate prostate cancer research, patient education and treatment. Several important initiatives and 3 key groups came together to make this possible.

1) Several years ago the AUA Board of Directors approved implementation of a plan to improve our advocacy efforts in the capital. Staff was hired

and a Washington, D. C. office was opened. A physician led Legislative Affairs Workgroup was created to coordinate physician involvement with the advocacy staff. In 2010 the workgroup became a full-fledged AUA committee. The efforts of the AUA Washington staff and physicians were critical in educating Congressional representatives to develop support for this bill.

2) The AUA Foundation developed the national prostate cancer awareness campaign "Know Your Stats About Prostate Cancer®" in collaboration with the National Football League (NFL) to improve awareness and increase education about prostate cancer. In the last year and especially walking around Washington recently I witnessed firsthand the power of this

partnership. The NFL was well represented by Harold Henderson, Executive Vice President and Senior Advisor to the NFL Commissioners, and George Martin, Executive Director and President, NFL Alumni.

"In an era of increasing deficits and public concern about the national debt, this bill does not ask for new money."

The AUA and AUA Foundation owe a special thanks to the NFL alumni and NFL Hall of Famers who have participated in this initiative. Mike Haynes, Hall of Famer who played with the New England Patriots and Oakland Raiders, spearheaded this effort and helped the AUA Foundation recruit other NFL alumni. Each time I listen to Mike

his story becomes more powerful. I'd like to thank Mike for all of his hard work. To read more go to <http://knowyourstats.org>.

3) There would not have been a bill without someone to write it and actively promote it in the halls of Congress. The AUA produced a bill capable of gaining traction through the joint efforts of several AUA staff members. Beth Kosiak, Ph.D., Associate Executive Director for Health Policy, formulated the key ideas; Karen Lencoski, J.D., Government Relations and Advocacy Federal Manager, relentlessly pressed members of Congress to support it; Brian Bailey, States and Sections Manager, and Jennifer Bertsch, Executive Coordinator for Health Policy, conducted the necessary background research; and Sue Ramthun, our external lobbyist from Hart Health Strategies, ensured that the legislative language was in order.

▼ Continued on page 21

Health Policy/Government Affairs

▼ Continued from page 20

The bill, known as the Prostate Research, Outreach, Screening, Testing, Access and Treatment Effectiveness (PROSTATE) Act of 2010 (S. 3775), requires the creation of a federal interagency task force, convened by the Secretary of Veterans Affairs, in collaboration with the Secretaries of Health and Human Services and Defense, to align current federal programs on prostate cancer to more efficiently and effectively address activities in the areas of 1) education and early detection, 2) research, 3) health care delivery, and 4) underserved populations in inner cities and rural areas. In an era of increasing deficits and public concern about the national debt, this bill does not ask for new money. Rather it asks for the monies currently allocated to be spent more wisely by identifying best practices and eliminating possible duplication. Given that addressing prostate

cancer effectively is a priority of the Department of Veterans Affairs and Department of Health and Human Services, it is possible that this bill may attract attention and support.

Now that this bill has been introduced, the next step is to get momentum behind it by obtaining cosponsors from both sides of the aisle, and get it on the legislative calendar for a hearing by the Senate HELP (Health, Education, Labor and Pensions) Committee and the House Committee on Oversight and Government Reform. If each committee passes the bill, it then goes to the floor for a vote. However, with limited time before the November elections, it is unclear whether the current Congress will get to the point of actually voting on this bill before or after the election. We fully expect that the momentum we have achieved with the introduction of the bill during Prostate Cancer Awareness Month and the support of the NFL will continue into January 2011 when the 112th Congress convenes. We will

continue to work hard for its passage.

There are several lessons to be learned from these efforts. Legislation has a long lead time, and requires the ongoing (perhaps years) and well coordinated efforts of experienced and articulate urologists, seasoned professional staff, and supporters like the general public, the NFL and patient advocates to be successful. Other areas, such as negotiating to change private insurer reimbursement policies, often have a shorter lead time but still require a comparable, carefully structured, broad effort.

The next major step to implement the Affordable Care Act, previously known as the Patient Protection and Affordable Care Act or the Healthcare Reform Act of 2010, is the writing of regulations by federal agencies such as Centers for Medicare and Medicaid Services which will further articulate such general concepts like Accountable Care Organizations included in the statute. To ensure that the unique needs and perspectives of urology are considered, we will need

to call on all of our resources to make sure that the federal government fully understands the implications of the decisions they make in the regulation process. This not only means submitting the comment letters the AUA staff carefully prepares in collaboration with our volunteer physicians, but also arranging targeted in-person visits by urologists and AUA staff with key federal officials at appropriate times.

Perhaps most importantly in this process is the element of teamwork. Because of the massive and complex environment produced by national health care reform, a well orchestrated effort by volunteer urologists, AUA staff, and powerful supporters such as the NFL and patient advocacy groups identified through the AUA Foundation, is essential to all of the activities in which we must be involved. A maximally effective team is one that draws on the expertise of all of its members. I urge you to consider becoming more engaged in AUA advocacy activities to advance and protect the field of urology. ♦

FROM THE Office of Research

Increasing the Talent Pool in Urological Research



Dr. Johannes Vieweg
Chair, Research Council
Gainesville, Florida

AUA Foundation Research Scholars Program

Since 1987 the Research Scholars Program of the AUA Foundation (AUA Foundation) has provided funding to approximately 500 young men and women interested in pursuing careers in urological research. These scholarships have allowed young scientists to begin research careers even while many urology departments across the country face serious budget constraints. A major objective of this program is to expand the number of physician-scientists who devote the majority of their professional efforts to seeking new knowledge about urological health and disease through the advancement of research.

Physician-scientists have a critical

role in bridging the gap between basic science researchers and practicing health care professionals, thus advancing scientific knowledge and biomedical innovation. Nevertheless, socioeconomic pressures, such as budget constraints, the need for generating clinical revenues and the lack of adequate research mentorship, create the risk of physician-scientists becoming an endangered species. The field of urology appears to be especially affected by a shortage of physician-scientists involved in fundable, patient oriented research.¹

The National Institutes of Health (NIH) awarded only \$59.3M to the field of urology in 2009, resulting in a poor ranking of 14 among 19 clinical science departments.² NIH grant submission rates by urological scientists are low, and at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) the number of R01 applications related to urology has been modest, with only approximately 50 applications submitted annually during the last 5 years.³

Interestingly, NIDDK data suggest that in urology the number of R01 awards mirrored the number of applications, and R01 success rates were similar to those in other NIDDK funded disciplines such as nephrology or hematology. Therefore, for the urology portfolio of R01s to show a meaningful increase, the number of new investigator applications must increase significantly. In view of these data there is an urgent need to increase the availability of talented researchers and establish a robust pipeline of young scientists who can successfully compete for federal funding.

“...for the urology portfolio of R01s to show a meaningful increase, the number of new investigator applications must increase significantly.”

The AUA Foundation Research Scholars Program has refocused its efforts as the premier urology research support program in the United States to address this unmet need by encouraging interest in urological research careers and ensuring that new talent will enter the field of urological research. The value of this program cannot be overstated

and it merits the continued support of the entire AUA membership.

Research Support at All Career Stages

A recent evaluation of the AUA Foundation Research Scholars Program revealed that since its inception, funded scholars have gone on to secure more than \$373.4M in federal (\$320.0M) and private (\$53.4M) research dollars to date (cumulative data). However, further analysis indicated that this success is attributable to only 20% of the 493 scholars, and that only this subset of scientists has moved on and attained research independence. So how can we improve the selection process for awarding AUA Foundation Research Scholarships so that future designees will be successful in competing for NIH funding and will make valuable contributions to the field of urological research?

We must address multiple issues to improve this process, including defining more rigorous selection criteria, assuring appropriate mentorship, promoting better comprehension of the grant process and enhancing communications with the NIH. Fortunately many educational programs and workshops provided by the AUA Foundation and other organizations have already begun to address some of these concerns. Other

▼ Continued on page 22

From the Office of Research

▼ Continued from page 21

mechanisms to increase the availability of scholars with NIH funding potential are to increase the talent pool of young investigators entering urology and support those with research interests during residency.

At present virtually all of the AUA research support portfolio is awarded to M.D. or M.D./Ph.D. investigators after their residency training, or to Ph.D.s who have already spent a significant amount of time in the research arena. Broadening funding to all career stages would increase the opportunities for attracting top students and residents to urology research, individuals who would otherwise go into dif-

ferent specialties or be unable to pursue research interests during training. In reality 80% to 90% of urology residents do not choose to pursue research careers, not because of a lack of conviction, but because of a lack of appropriate training, encouragement and mentorship as medical students or during urology residency.

Conducting research during residency is a challenge since the Centers for Medicare and Medicaid Services (CMS) restrict time spent on patient oriented research. However, approximately 35% of all U.S. urology residency programs offer a protected research year, although this research year must be performed as a time-out outside the scope of the CMS supported residency program.⁴ New

research award mechanisms for residents may encourage other urology programs to request these time-outs and grant dedicated research time for select house staff with research interests. At the student level additional educational conferences and workshops would encourage more students to consider a urology career, which could be the catalyst for increased interest in urology research.

In the coming months the Office of Research will be working to enhance our capacity to attract the best and brightest young scientists to pursue careers in urology, thus shaping the future of our specialty through their research contributions. We propose to refine the scholar selection criteria and broaden funding to include earlier

career stages. Mentorship guidelines will continue to be improved, as will communications with the NIH and other public and private granting agencies. As this process goes forward your feedback and continued support will have a critical role in ensuring our progress. ♦

1. Lange PH: Genitourinary oncology and its surgeon scientists: triumphant past, but does it have a future? *Urol Oncol* 2007; **25**: 2.
2. Blue Ridge Institute for Medical Research, 2009. Available at www.brimr.org.
3. Robert Star, MD, Director, Division of Kidney, Urologic, and Hematologic Diseases, NIDDK: Personal communication.
4. Accreditation Council for Graduate Medical Education (ACGME) Data Resource Book 2007. Available at www.acgme.org.

FROM YOUR Foundation



Sandra Vassos, MPA
Executive Director,
AUA Foundation
Linthicum, Maryland

New Basic Science Symposium

The AUA Foundation continues to work on renewing and increasing the emphasis on research at the AUA annual meeting. We are proud that the last few years have seen a resurgence of interest in the annual Research Forum and Grantscraft Course, as well as an increase in the number of poster and podium presentations, and sessions led by past scholars and awardees.

The AUA Foundation Office of Research and the Society for Basic Urologic Research leadership have joined with program officers from the National Institute of Diabetes and Digestive and Kidney Diseases to develop an annual Basic Science Symposium to be held the Friday preceding the AUA annual meeting beginning in 2011 in Washington, D. C. This annual symposium will address an overarching area in research that has the transformational potential to impact the practice of urology across the spectrum of urological diseases. Topics will be selected annually based on the expertise available around the host city.

The 2011 Basic Science Sym-

posium will be held on Friday, May 13 (1:00 to 6:00 p.m.) on "Stem Cells in Urologic Development and Disease." A program agenda will be available in early 2011, so you can add this important program to your AUA annual meeting itinerary. For more information contact the Office of Research at research@auafoundation.org or telephone 410-689-3929.

UrologyHealth.org to be Re-Launched

You asked and we listened. So many AUA members have told us how much they appreciate the urologist written and vetted patient information available on our website, www.UrologyHealth.org. However, many are frustrated (as are their patients) with navigating the current online setup. An exciting new look is on the horizon for the AUA Foundation website and we are looking forward to showing it off!

The site will be undergoing a major renovation in early 2011 to increase functionality, provide a hub for research information, grants and updates on funded projects, create a user-friendly experience for patients and physicians, and launch a new portal to generate support for our mission based programs. Look for more information in upcoming issues of *AUANews*. The Foundation is working hard to improve resources for you and your patients. ♦

GRADUATE MEDICAL Education News

Resident Education and the AUA Core Curriculum



Dr. Beau N. Dusseault
Residents Committee
Southeastern Section
Representative
Lexington, Kentucky

The American Urological Association (AUA) mission is, "To promote the highest standards of urological clinical care through education, research and in the formulation of health care policy." There are many components to education in urology, including but not limited to basic science research, clinical knowledge and clinical skills.

Not long ago the standardization of urological education for medical students was deemed necessary and, thus, the National Medical Student Core Curriculum was created. This curriculum set the standard for what the urological community, represented by residency directors as well as medical students, believed was vitally important for all physicians to have been taught during their medical school education. This project was well received and a similar effort was undertaken for formal urology training. The AUA Core Curriculum project began in 2006, and was finalized and revealed to the international urological community in San Francisco at the 2010 AUA meeting.

The Core Curriculum is an online tool for education in the areas that con-

stitute the standard knowledge foundation that residents must acquire during training. It is divided into 50 sections that encompass what is considered the whole of urology. This tool not only lists what is deemed important, but it also references every point with a salient article, book chapter or other appropriate reference. In most instances the user of the Core Curriculum can retrieve the original reference with a simple click of the mouse, and how to find information related to the objectives and contents is clearly explained. The Core Curriculum also includes an exhaustive list of references that can be used for further research or clinical publications.

Dr. Stephen E. Strup, a contributing author for the section on Upper Urinary Tract Obstruction and Ureteropelvic Junction Obstruction, stated that "The AUA Core Curriculum was designed to be a comprehensive, yet fluid, source of urological knowledge. It represents the core knowledge in Urology that should be mastered...[The greatest strength is that] the core curriculum can be easily adapted and modified by changing that particular section and updating the links rather than having to wait for a new edition to be printed."

Residency education is a multifaceted charge given to various training

▼ Continued on page 23

Graduate Medical Education News

▼ Continued from page 22

programs across the nation. This task includes instilling critical thinking skills, laying a large foundation of knowledge, developing surgical technique and knowledge of many procedural interventions, and conveying the fundamentals of research. This massive undertaking must be accomplished

while creating a physician who looks to the interest of the patient, and provides efficient, cost-effective and ethical medical care to various populations. The graduating urology resident must be well trained, and able to successfully complete the written and oral certification examinations given by the American Board of Urology. Dr. Strup believes that “by mastering the core knowledge reflected in the curriculum,

the urology trainee and practitioner should be well prepared for in-service and board testing that is designed to test this ‘core knowledge.’”

While education is a cornerstone of the AUA, urology resident education is a uniquely important part of its role in serving the public at large. The training of future urologists sets the stage for the development and continued progress the AUA has seen since its

beginnings in 1902. To maintain the highest standards and expect competent, well trained, thoughtful physicians to enter into practice it is vital to be able to clearly identify what is expected of their education. The development of the Core Curriculum has showcased this privilege and responsibility of the AUA in promoting this more fluid and comprehensive educational process. ♦

MANAGING *Your Practice*

Stocks and Bonds—What Mixture is Right for You?

Joel M. Blau, CFP® and
Ronald J. Paprocki, JD, CFP®, CHBC
Chicago, Illinois

Investors have come to realize that choosing the proper basic stock-bond mix is an integral first step in portfolio design. Although the decision may appear simple, it can have a profound impact on future wealth. Portfolio theory explains the value of making a deliberate, strategic decision about the proportion of stocks vs bonds to hold in a portfolio. The premise is that when constructing portfolios all investors face the 2 important issues of 1) how much risk to take, and 2) how to balance a portfolio of risky assets (equities/stocks) and less risky assets (fixed income/ bonds) to achieve that desired level of risk.

Investors willing to take stock risk should begin with a diversified market portfolio. In its simplest form each investor can then dial down total risk in the portfolio by adding fixed income to the mix. The greater the bond allocation relative to stocks, the less risky the portfolio and the lower the total expected return. The greater the stock allocation relative to bonds, the higher the expected return and risk of the portfolio. Investors who want to take even more risk than the market can increase exposure by borrowing on margin and/or adding more aggressive equity asset groups that offer higher expected returns for the higher risk being taken.

So how does one decide how much to allocate between stocks and bonds? A common method is to evaluate model portfolios along the risk-return spectrum. A riskier portfolio

holds 100% stocks and the least volatile portfolio holds 100% bonds. Between these extremes lie standard stock-bond allocations such as 80%-20%, 60%-40%, 40%-60% and 20%-80%. You can then compare the average annualized return and volatility (standard deviation) of each model portfolio for periods such as 1, 3, 5, 10 and 20 years. Volatility is one of several risk measures investors may want to consider. With this in mind the analysis should feature average returns as well as best and worst case returns for the various periods.

While this technique relies on historical performance that may not repeat in the future and does not consider various investment costs, it may help you think about the risk-return tradeoff, and visualize and quantify the range of potential outcomes based on the aggressiveness of the strategy.

After establishing the basic stock-bond mix, investors can turn their attention to the stock allocation, where the best opportunities to refine the risk-return tradeoff are found. Investors comfortable with higher doses of equity risk can overweight or “tilt” their allocation toward riskier asset classes that have a history of offering average returns above the market. As an example, researchers have found that small cap stocks have had higher average returns than large cap stocks. By holding a larger portion of small cap stocks in a portfolio, an investor increases the potential to earn higher returns for the additional risk taken.

The final step in refining the stock component is to diversify globally. By holding an array of equity asset classes

across domestic and international markets, investors can reduce the impact of under performance in a single market or region of the world. Although the markets may experience varying levels of return correlation, this diversification can further reduce volatility in a portfolio, which may translate into higher compounded returns over time.

Mr. Blau and Mr. Paprocki welcome readers’ questions. They can be reached at 800-883-8555, or at blau@mediquis.com or paprocki@mediquis.com. ♦

The opinions expressed in this report are those of the authors and are not necessarily those of Ausdal Financial Partners, Inc. The material has been prepared or distributed solely for information purposes and is not a solicitation or an offer to buy any security.

Investors in mutual funds should carefully consider the investment objectives, risks, charges and expenses. This and other important information is contained in the prospectus, which can be obtained from your investment professional and should be read carefully before investing. Investments are not FDIC insured, nor are they deposits of or guaranteed by a bank or any other entity. Please consult your tax advisor regarding any questions you may have with respect to your personal tax liability.

Securities offered through Joel M. Blau, CFP® and Ronald J. Paprocki, JD, CFP®, CHBC, registered representatives of Ausdal Financial Partners, Inc. Member FINRA/SIPC. MEDIQUIS Asset Advisors, Inc. and Ausdal Financial Partners, Inc. are independently owned and operated.

Feeling Lucky? Don't Gamble with your Practice!

Learn more about PQRI.

The AUA can help you understand and properly participate in the Physician Quality Reporting Initiative (PQRI).

The AUA's CD Mastering the Basics of PQRI is now available



American
Urological
Association, Inc.

To learn more about PQRI and our latest CD
Visit www.AUAnet.org/PQRIToolkit

HISTORY Corner

Cello Scrotum Cured



Dr. Lawrence M. Wyner*
Huntington, West Virginia

Medical ailments of musicians have been described for the last 3 centuries, beginning with the Bernardino

Ramazzini, who is now acclaimed as the father of occupational medicine (fig. 1). Ramazzini was a distinguished professor at the University of Padua, Italy, whose early career focused on the diagnosis and treatment of malaria. One day he hired some men to clean out the cesspit at his home, and subsequently witnessed one of them being overcome by fumes.



Fig. 1. Bernardino Ramazzini, 1633–1714

Keen observer that he was, Ramazzini realized that this case of “bad air” was work related, and served as the springboard for his 1713 magnum opus, *De Morbis Artificum Diatriba* (Diseases of Workers), a monumental effort in which he studied 52 occupations or groups of people, describing the medical ailments peculiar to their role in society. With every patient encounter Ramazzini exhorted his reader to inquire “What do you do for a living?” as a part of taking a medical history. In addition to its watershed effect on the practice of medicine and public health, it also provides us with a window into life in the century preceding the Industrial Revolution.

Buried among the descriptions of ailments of miners, farmers, scribes and manufacturers is a chapter devoted to the trials and tribulations of musicians. Calling on his own observations as well as those of his colleagues, Ramazzini gives examples of hernias and gastrointestinal hemorrhages occurring in

singers and players of wind instruments, probably as a result of prolonged and exaggerated diaphragmatic excursion, or perhaps more simply by bad technique. For example, he says,

In his *Observations*, Diemerbroeck gives a pitiable case of a flutist who, when certain others were playing the trumpet, was so ambitious to play louder than they that he ruptured a large vein in the lung, had a violent hemorrhage, and died within two hours.¹

Yet despite these ailments, the musicians of Ramazzini’s day had not yet acquired the virtuosic aspirations of their successors. Music performance in the 17th century was rooted in the nobility and the Church, and the idea of an individual superstar performer was still years in the future. However, by the mid 1800s the possibility of a young man or woman becoming a renowned soloist was now a probability, at least for anyone who was willing to work hard enough at it. Musicians of this era were bent on pushing the limits of human ability, and music that had once been heavenly now became fiendishly difficult to play, leading to further challenges.

This set the stage, so to speak, for George Vivian Poore, an internist of the Victorian era in London (fig. 2). Poore was an eminent physician who had many professional interests, not unlike Prof Henry Higgins in *My Fair*



Fig. 2. George Vivian Poore, 1843–1904



Fig. 3. Dr. Elaine Murphy and Mr. John Murphy, c. 1974

Lady. He was especially interested in studying the neuromuscular injuries that may occur following repetitive motions, and the hordes of young people trying to master the music of Beethoven, Chopin and Brahms provided a ready supply of patients.

In 1887 the *British Medical Journal* (BMJ) became the first scientific periodical to publish a study of a musician’s ailment, a study by Poore of muscle cramping in piano players which he called “pianist’s breakdown.”² He wrote,

Piano-playing, if not prohibited altogether, must only be practiced to a degree short of that which causes pain or annoyance. It is often difficult to restrain the ardour of these patients in the matter of playing. Directly they feel in a small degree better, they fly to the piano; and I have known the progress of more than one case very seriously retarded by the undoing, as it were, of the good effect of rest by an hour’s injudicious and prohibited ‘practicing.’

These endeavors spawned the field of performance medicine, which has since grown to encompass multiple textbooks and journals dedicated to this topic. In addition to the hernias and hemorrhages that Ramazzini treated, care of the modern musician is comprehensive, and may range from treatment of musculoskeletal problems and hearing loss to stage fright and stress related illnesses. Recent literature suggests that the majority of modern symphony orchestra players have experienced 1 or more of these conditions during the course of their careers.³

For example, in 1935 trumpeter Louis Armstrong hurt his lips from too much playing and had to lay down his horn for a year. His condition was diagnosed as a rupture of the orbicularis oris muscle and was referred to as Satchmo’s syndrome. Other musician ailments soon followed, affecting string,

woodwind, brass and percussion players alike, ascribed to the vagaries of the various musical instruments. However, perhaps the envelope was pushed a bit too far by Curtis, who reported cystic mastitis in 3 adolescent girls learning to play classical guitar, presumably from pressure on the breast from the edge of the sound box, a condition he called “guitar nipple.”⁴

Enter Dr. Elaine Murphy, at the time a young registrar in psychiatry, and her husband John, a businessman, both avid readers of the *BMJ* (fig. 3). Both doubted the authenticity of “guitar nipple,” and so they decided to perform a public service by sending in their own spoof to the *BMJ*. They wrote about a condition called cello scrotum, claiming to have seen a cellist patient with chronic groin irritation due to long hours of scrotal contact with the vibrating body of the instrument.⁵ Dr. Murphy later explained, “We cooked all this up after reading this letter about guitar nipple. John used to read the *BMJ* too and after dinner one night, I guess after a glass or two of wine, we composed this letter.”⁶ To their surprise the *BMJ* published the letter, and wire services reported the phenomenon worldwide. Musicians unions in the United Kingdom and Soviet Union lobbied to have the condition declared an industrial disease.⁷ Reportedly an entire Russian symphony orchestra cello section was affected.⁸

Cello scrotum would be referenced at least a dozen times in the peer reviewed medical literature during the next 35 years, although skeptics questioned how the body of the cello could contact the scrotum if the instrument were played properly.^{9,13} These naysayers pointed out that the cellist would have to be doing something fairly extreme for this to occur. With apologies to Sir Percivall Pott, one wag suggested that the affected cellists were

History Corner

▼ Continued from page 24

moonlighting as chimney sweeps¹³ while another implicated the chair rather than the cello itself.¹⁴

In any case the Murphys decided to come clean after witnessing yet another review article referencing their creation in 2008,¹⁵ and sent a letter of retraction to the *BMJ* later that year, admitting that cello scrotum was indeed a high-brow hoax.¹⁶ By this time they had advanced their careers considerably.

John Murphy had become a successful entrepreneur as chairman of St. Peter's Brewery in Suffolk, where his products have earned international renown. Dr. Elaine Murphy had been elevated in 2004 to the House of Lords, where she sits on the panel overseeing the National Health Service, and advises the Crown on matters pertaining to geriatric mental health and Alzheimer's disease. Although her cello scrotum days are now over, her work still undergoes "peer" review.

In addition to being one of the more ridiculous episodes in the history of urology (the Murphys' revelation garnered the number 2 spot on *Time* magazine's "Top Ten Oddball News Stories of 2009"), cello scrotum may have helped to coin the word "scrotum-gate," which was the moniker bestowed on the affair by *BMJ* staffers, although in reality the term had been used 2 years before the Murphy revelation. It appears that the literary community was in an uproar over the use of the word scrotum on the opening page of a children's book (even an award winning one) and applied scrotum-gate first in reference to this controversy.¹⁷

In the final analysis the ultimate legacy of cello scrotum is the admission by *BMJ* editors that journalistic fraud is indeed taken seriously but that in this particular case no one was harmed by the lighthearted deception and everyone had a good laugh. They awarded Baroness Murphy the Hoax of the Century award at their annual Christmas party, and vowed that the *BMJ* would continue its pioneering efforts on behalf of musicians' health. ♦

*Financial interest and/or other relationship with Novartis and Pfizer.

1. Ramazzini B: Diseases of singers and musicians. In: *De Morbis Artificum Diatriba* (Diseases of Workers). Translated by WC Wright. Chicago: University of Chicago Press 1940, p 335.
2. Poore GV: Clinical lecture on certain conditions of the hand and arm which interfere with the performance of professional acts, especially piano-playing. *Br Med J* 1887; **1**: 441.
3. Abreu-Ramos AM and Micheo WF:

- Lifetime prevalence of upper-body musculoskeletal problems in a professional-level symphony orchestra: age, gender, and instrument-specific results. *Med Probl Perform Art* 2007; **22**: 97.
4. Curtis P: Letter: guitar nipple. *Br Med J* 1974; **2**: 226.
5. Murphy JM: Letter: cello scrotum. *Br Med J* 1974; **2**: 335.
6. Murphy E: Personal communication.
7. Murphy JM: BBC News interview, Jan. 28, 2009.
8. Murphy JM: Personal communication.
9. Lockwood AH: Medical problems of musicians. *N Engl J Med* 1989; **320**: 221.
10. Rimmer S and Spielvogel RL: Dermatologic problems of musicians. *J Am Acad Dermatol* 1990; **22**: 657.
11. Harvell J and Maibach HI: Skin disease among musicians. *Med Probl Perform Art* 1992; **7**: 114.
12. Liu S and Hayden GF: Maladies in musicians. *South Med J* 2002; **95**: 727.
13. Scheuer PJ: Letter: musical bumps. *Br Med J* 1974; **2**: 504.
14. Shapiro PE: "Cello scrotum" questioned. *J Am Acad Dermatol* 1991; **24**: 665.
15. Bache S and Edenborough F: A symphony of maladies. *BMJ* 2008; **337**: a2646.
16. Murphy E and Murphy JM: Cello scrotum confession. *Murphy's lore*. *BMJ* 2009; **338**: b288.
17. Bosman J: With one word, children's book sets off uproar. *The New York Times Book Review*, Feb. 18, 2007.

Save the Date!

March 27-29, 2011 • Washington, DC

Registration is free!
Register online (starting January) at www.UROPAC.org

Questions? E-mail GovernmentRelations@AUAnet.org
Watch your e-mail for more details!

 American Urological Association, Inc.[®]

 AACU
American Association of Clinical Urologists, Inc.

CALENDAR *of Events*

November 2010

November 5–6
Robotic Surgery Beyond the Prostate

Winston-Salem, North Carolina
Wake Forest University Baptist Medical Center
krchrdsn@wfubmc.edu
www.wfubmc.edu/school/urology/CME-credits.htm

November 6–7
AUA Mentored Renal Laparoscopy: A Skills and Knowledge-Based Approach

Houston, Texas
Houston Marriott Medical Center
800-908-9414
registration@auanet.org
www.auanet.org/content/courses/MLAP101/

November 11–14
Sexual Medicine Society of North America Annual Meeting

Miami Beach, Florida
Loews Miami Beach Hotel
847-264-5949
info@smsna.org
www.smsna.org

November 11–14
SBUR Fall Symposium

Atlanta, Georgia
Grand Hyatt Atlanta
847-517-7225
nathan@wjweiser.com
www.sbur.org

November 12–13
AUA Tissue Ablative Course: Kidney and Prostate

Miami, Florida
University of Miami
Miller School of Medicine
800-908-9414
registration@auanet.org
www.auanet.org/content/courses/TAC101/

November 20
AUA Oncology Knowledge Assessment Test

Various sites throughout the U.S. and Canada
410-689-3783
exams@auanet.org

November 20
AUA In-Service Examination

Various sites throughout the U.S. and Canada
410-689-3783
exams@auanet.org

December 2010

December 3–4
LESS in Urology: A Comprehensive Course on Laparoendoscopic Single Site Surgery

Dallas, Texas
University of Texas Southwestern Medical Center
800-908-9414
registration@auanet.org
www.auanet.org/content/courses/LESSF210

December 10–11
AUA Urolithiasis Update

Washington, D. C.
Park Hyatt Washington
800-908-9414
registration@auanet.org
www.auanet.org/content/courses/URU101

CLASSIFIED Advertising



Get in gear.

You're a creative, innovative professional who's already mastered some of your field's most challenging terrain. Now you're ready to shift into a whole new gear. So make tracks for Mercy Medical Group in Sacramento, CA, a service of CHW Medical Foundation. Located in picturesque Northern California, our community offers leisurely bike trails along the Sacramento River, as well as exciting adventures in the nearby Sierra foothills. Join us and discover a working environment, career opportunity and recreational amenities that are more than worth the ride.

UROLOGIST
Sacramento, CA

We're seeking a BE/BC physician to provide excellent patient care and practice full-scope general urology. Our Urologists maintain a comfortable weekend call schedule of 1:9 and have access to Hospitals 24/7 and to da Vinci Robotics. As a member of our team, you'll also benefit from a supportive staff, a congenial work environment and an excellent, built-in referral system.

CHW/MF is affiliated with Catholic Healthcare West, one of the leading healthcare systems in the country. Our physicians utilize leading edge technology, including EMR and enjoy a comprehensive and excellent compensation and benefits package. Sacramento offers affordable housing, outstanding schools, lots of cultural and recreational options and a great location that's just 90 minutes away from scenic Lake Tahoe. This a shareholder-track position with bonus potential and a very desirable retirement plan.

For more information, please contact
or send CV to: Colin Harris, Physician Recruiter
colin.harris@chw.edu
P: (916) 733-3415 F: (916) 859-1875

www.mymercymedicalgroup.org



AUANews
Classified Advertising Information

Classified space is for advertising positions available, open faculty positions, course announcements, seminars, meetings and educational courses.

Display Advertising Rates

Ad Size	1x	3x
Full Page	\$2,065	\$2,020
1/2 Page	\$1,695	\$1,620
1/4 Page	\$ 920	\$ 885
1/6 Page	\$ 660	\$ 650
Blind Box Services \$40 per issue		

Line Advertising Rates

\$235 for the first 50 words
\$4.55 for every word thereafter

Closing Date & Cancellations:

Copy must be received six weeks in advance of the month in which the ad is to appear. Cancellation requests must be made in written form by fax, e-mail or postal mail and will be honored for the earliest applicable issue.

**ALL ADS
MUST BE PREPAID**

Contact:

Rhonda Beamer
rhonda.beamer@wt-group.com
P: 443-512-8899 x. 106 F: 443-512-8909

**SIU2011
berlin**

31st CONGRESS OF THE SOCIÉTÉ INTERNATIONALE D'UROLOGIE
ICC BERLIN ▶ October 16-20 ▶ 2011

WITH THE
5th Conference of the World Urological Oncology Federation
October 15-16, 2011
www.wuof.org

Featuring the ICUD CONSULTATION ON PROSTATE CANCER

▶ ABSTRACT SUBMISSION DEADLINE: APRIL 1, 2011

www.siucongress.org

Help your patients' families with the frustration of nocturnal enuresis

Your patients' families find what they need to support your treatment plan at the Bedwetting Store, America's favorite source for alarms, waterproof bedding, books and supplies.

Call **1-800-214-9605** for a supply of catalogs.

- Bedwetting alarms
- Waterproof bedding
- Vibrating watches
- Books on bedwetting

Order your **FREE** patient catalogs.

Bedwetting Store™
www.bedwettingstore.com

*Jalyn*TM

*(dutasteride and tamsulosin HCl)
Capsules
0.5 mg / 0.4 mg*

Available in bottles as follows:

Bottle of 30

Bottle of 90

